BCL-6	B-protein
mutations	O
in	O
normal	B-cell_type
germinal	I-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
:	O
evidence	O
of	O
somatic	O
hypermutation	O
acting	O
outside	O
Ig	B-DNA
loci	I-DNA
.	O

The	O
molecular	O
mechanism	O
involved	O
in	O
the	O
process	O
of	O
antigen-driven	O
somatic	O
hypermutation	O
of	O
Ig	B-DNA
genes	I-DNA
is	O
unknown	O
,	O
but	O
it	O
is	O
commonly	O
believed	O
that	O
this	O
mechanism	O
is	O
restricted	O
to	O
the	O
Ig	B-DNA
loci	I-DNA
.	O

B	B-cell_type
cell	I-cell_type
lymphomas	I-cell_type
commonly	O
display	O
multiple	O
somatic	O
mutations	O
clustering	O
in	O
the	O
5'-regulatory	B-DNA
region	I-DNA
of	O
BCL-6	B-protein
,	O
a	O
proto-oncogene	B-DNA
encoding	O
for	O
a	O
POZ/Zinc	B-protein
finger	I-protein
transcriptional	I-protein
repressor	I-protein
expressed	O
in	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
required	O
for	O
GC	O
formation	O
.	O

To	O
determine	O
whether	O
BCL-6	B-protein
mutations	O
represent	O
a	O
tumor-associated	O
phenomenon	O
or	O
reflect	O
a	O
physiologic	O
mechanism	O
,	O
we	O
screened	O
single	O
human	B-cell_type
tonsillar	I-cell_type
GC	I-cell_type
B	I-cell_type
cells	I-cell_type
for	O
mutations	O
occurring	O
in	O
the	O
BCL-6	B-DNA
5'-noncoding	I-DNA
region	I-DNA
and	O
in	O
the	O
Ig	B-DNA
variable	I-DNA
heavy	I-DNA
chain	I-DNA
sequences	I-DNA
.	O

Thirty	O
percent	O
of	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
displayed	O
mutations	O
in	O
the	O
742	B-DNA
bp	I-DNA
region	I-DNA
analyzed	O
within	O
the	O
first	O
intron	O
of	O
BCL-6	B-protein
(	O
overall	O
frequency	O
:	O
5	O
x	O
10	O
(	O
-4	O
)	O
/bp	O
)	O
.	O

Accordingly	O
,	O
an	O
expanded	O
survey	O
in	O
lymphoid	O
malignancies	O
showed	O
that	O
BCL-6	B-protein
mutations	O
are	O
restricted	O
to	O
B	O
cell	O
tumors	O
displaying	O
GC	O
or	O
post-GC	O
phenotype	O
and	O
carrying	O
mutated	B-DNA
Ig	I-DNA
variable	I-DNA
heavy	I-DNA
chain	I-DNA
sequences	I-DNA
.	O

These	O
results	O
indicate	O
that	O
the	O
somatic	O
hypermutation	O
mechanism	O
active	O
in	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
physiologically	O
targets	O
non-Ig	B-DNA
sequences	I-DNA
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

95	NULL
,	NULL
pp	NULL
.	NULL

11816-11821	NULL
,	NULL
September	NULL
1998	NULL
Immunology	NULL
BCL-6	NULL
mutations	NULL
in	NULL
normal	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
:	NULL
Evidence	NULL
of	NULL
somatic	NULL
hypermutation	NULL
acting	NULL
outside	NULL
Ig	NULL
loci	NULL
LAURA	NULL
PasouvaALUCCI*T	NULL
,	NULL
Anna	NULL
MiGuiazza**t	NULL
,	NULL
NICOLA	NULL
FRACCHIOLLAF	NULL
,	NULL
CHRISTOPHER	NULL
WILLIAM*	NULL
,	NULL
ANTONINO	NULL
NERI4	NULL
,	NULL
LUCA	NULL
BALDINIE	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
ULF	NULL
KLEINY	NULL
,	NULL
RaLr	NULL
AND	NULL
RICCARDO	NULL
DALLA-FAVERA	NULL
*I	NULL
*Departments	NULL
of	NULL
Pathology	NULL
and	NULL
Genetics	NULL
and	NULL
Development	NULL
,	NULL
Columbia	NULL
University	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10032	NULL
;	NULL
Servizio	NULL
di	NULL
Ematologia	NULL
,	NULL
Istituto	NULL
di	NULL
Scienze	NULL
Mediche	NULL
,	NULL
Universita	NULL
'	NULL
di	NULL
Milano	NULL
,	NULL
Ospedale	NULL
Maggiore	NULL
Istituto	NULL
di	NULL
Ricoveroe	NULL
Cura	NULL
a	NULL
Carattere	NULL
Scientifico	NULL
,	NULL
Milan	NULL
20122	NULL
,	NULL
Italy	NULL
;	NULL
§Department	NULL
of	NULL
Human	NULL
Genetics	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10021	NULL
;	NULL
and	NULL
``	NULL
Institute	NULL
of	NULL
Genetics	NULL
,	NULL
University	NULL
of	NULL
Cologne	NULL
,	NULL
Cologne	NULL
50931	NULL
,	NULL
Germany	NULL
Communicated	NULL
by	NULL
Maithew	NULL
D.	NULL
Scharff	NULL
,	NULL
Albert	NULL
Einstein	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Bronx	NULL
,	NULL
NY	NULL
,	NULL
August	NULL
6	NULL
,	NULL
1998	NULL
(	NULL
received	NULL
for	NULL
review	NULL
June	NULL
8	NULL
,	NULL
1998	NULL
)	NULL
ABSTRACT	NULL
The	NULL
molecular	NULL
mechanism	NULL
involved	NULL
in	NULL
the	NULL
process	NULL
of	NULL
antigen-driven	NULL
somatic	NULL
hypermutation	NULL
of	NULL
Ig	NULL
genes	NULL
is	NULL
unknown	NULL
,	NULL
but	NULL
it	NULL
is	NULL
commonly	NULL
believed	NULL
that	NULL
this	NULL
mechanism	NULL
is	NULL
restricted	NULL
to	NULL
the	NULL
Ig	NULL
loci	NULL
.	NULL

B	NULL
cell	NULL
lymphomas	NULL
commonly	NULL
display	NULL
multiple	NULL
somatic	NULL
mutations	NULL
clustering	NULL
in	NULL
the	NULL
5'-regulatory	NULL
region	NULL
of	NULL
BCL-6	NULL
,	NULL
a	NULL
proto-oncogene	NULL
encoding	NULL
for	NULL
a	NULL
POZ/Zinc	NULL
finger	NULL
transcriptional	NULL
repressor	NULL
expressed	NULL
in	NULL
germinal	NULL
center	NULL
(	NULL
GC	NULL
)	NULL
B	NULL
cells	NULL
and	NULL
required	NULL
for	NULL
GC	NULL
formation	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
BCL-6	NULL
mutations	NULL
represent	NULL
a	NULL
tumor-associated	NULL
phenomenon	NULL
or	NULL
reflect	NULL
a	NULL
physiologic	NULL
mechanism	NULL
,	NULL
we	NULL
screened	NULL
single	NULL
human	NULL
tonsillar	NULL
GC	NULL
B	NULL
cells	NULL
for	NULL
mutations	NULL
occurring	NULL
in	NULL
the	NULL
BCL-6	NULL
5'-noncoding	NULL
region	NULL
and	NULL
in	NULL
the	NULL
Ig	NULL
variable	NULL
heavy	NULL
chain	NULL
sequences	NULL
.	NULL

Thirty	NULL
percent	NULL
of	NULL
GC	NULL
B	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
naive	NULL
B	NULL
cells	NULL
,	NULL
displayed	NULL
mutations	NULL
in	NULL
the	NULL
742	NULL
bp	NULL
region	NULL
analyzed	NULL
within	NULL
the	NULL
first	NULL
intron	NULL
of	NULL
BCL-6	NULL
(	NULL
overall	NULL
frequency	NULL
:	NULL
5	NULL
x	NULL
10~+/bp	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
an	NULL
expanded	NULL
survey	NULL
in	NULL
lymphoid	NULL
malignancies	NULL
showed	NULL
that	NULL
BCL-6	NULL
mutations	NULL
are	NULL
restricted	NULL
to	NULL
B	NULL
cell	NULL
tumors	NULL
displaying	NULL
GC	NULL
or	NULL
post-GC	NULL
phenotype	NULL
and	NULL
carrying	NULL
mutated	NULL
Ig	NULL
variable	NULL
heavy	NULL
chain	NULL
sequences	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
somatic	NULL
hypermutation	NULL
mechanism	NULL
active	NULL
in	NULL
GC	NULL
B	NULL
cells	NULL
physiologically	NULL
targets	NULL
non-Ig	NULL
sequences	NULL
.	NULL

Somatic	NULL
hypermutation	NULL
is	NULL
one	NULL
of	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
Ig	NULL
genes	NULL
are	NULL
modified	NULL
in	NULL
B	NULL
cells	NULL
to	NULL
generate	NULL
a	NULL
large	NULL
repertoire	NULL
of	NULL
B	NULL
lymphocytes	NULL
,	NULL
each	NULL
expressing	NULL
a	NULL
unique	NULL
antibody	NULL
molecule	NULL
(	NULL
1	NULL
)	NULL
.	NULL

This	NULL
process	NULL
is	NULL
activated	NULL
in	NULL
germinal	NULL
center	NULL
(	NULL
GC	NULL
)	NULL
B	NULL
cells	NULL
(	NULL
2-4	NULL
)	NULL
,	NULL
where	NULL
it	NULL
introduces	NULL
mutations	NULL
in	NULL
the	NULL
variable	NULL
region	NULL
of	NULL
Ig	NULL
genes	NULL
(	NULL
IgV	NULL
)	NULL
at	NULL
a	NULL
frequency	NULL
of	NULL
2-8	NULL
x	NULL
10-2	NULL
in	NULL
humans	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
involved	NULL
in	NULL
IgV	NULL
hypermutation	NULL
is	NULL
not	NULL
known	NULL
,	NULL
although	NULL
experimental	NULL
evidence	NULL
suggests	NULL
that	NULL
it	NULL
requires	NULL
transcription	NULL
of	NULL
the	NULL
target	NULL
sequences	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
Ig	NULL
enhancer	NULL
but	NULL
not	NULL
a	NULL
specific	NULL
promoter	NULL
(	NULL
6-8	NULL
)	NULL
.	NULL

It	NULL
is	NULL
generally	NULL
assumed	NULL
that	NULL
the	NULL
process	NULL
of	NULL
somatic	NULL
hypermutation	NULL
is	NULL
restricted	NULL
to	NULL
the	NULL
Ig	NULL
loci	NULL
including	NULL
heavy	NULL
and	NULL
light	NULL
chain	NULL
variable	NULL
region	NULL
genes	NULL
(	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
B	NULL
cell	NULL
lymphomas	NULL
were	NULL
shown	NULL
to	NULL
display	NULL
somatic	NULL
hypermutation	NULL
of	NULL
the	NULL
5'-noncoding	NULL
region	NULL
of	NULL
BCL-6	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
,	NULL
a	NULL
proto-oncogene	NULL
encoding	NULL
a	NULL
POZ/Zinc	NULL
finger	NULL
transcriptional	NULL
repressor	NULL
normally	NULL
expressed	NULL
within	NULL
GC	NULL
B	NULL
cells	NULL
and	NULL
required	NULL
for	NULL
GC	NULL
formation	NULL
(	NULL
11-20	NULL
)	NULL
.	NULL

In	NULL
30	NULL
%	NULL
of	NULL
diffuse	NULL
large	NULL
cell	NULL
lymphoma	NULL
(	NULL
DLCL	NULL
)	NULL
and	NULL
5-10	NULL
%	NULL
of	NULL
follicular	NULL
lymphoma	NULL
(	NULL
FL	NULL
)	NULL
,	NULL
the	NULL
BCL-6	NULL
gene	NULL
is	NULL
altered	NULL
structurally	NULL
by	NULL
chromosomal	NULL
translocations	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
mutations	NULL
of	NULL
its	NULL
5'-noncoding	NULL
region	NULL
were	NULL
frequently	NULL
found	NULL
in	NULL
DLCL	NULL
and	NULL
FL	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
translocations	NULL
involving	NULL
this	NULL
locus	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

In	NULL
most	NULL
tumor	NULL
cases	NULL
,	NULL
mutations	NULL
were	NULL
multiple	NULL
,	NULL
often	NULL
biallelic	NULL
,	NULL
and	NULL
clustered	NULL
in	NULL
the	NULL
5	NULL
'	NULL
regulatory	NULL
sequences	NULL
at	NULL
frequencies	NULL
(	NULL
7	NULL
X	NULL
107	NULL
``	NULL
through	NULL
1.6	NULL
X	NULL
10-*/bp	NULL
)	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1998	NULL
by	NULL
The	NULL
National	NULL
Academy	NULL
of	NULL
Sciences	NULL
0027-8424/98/9511816-6	NULL
$	NULL
2.00/0	NULL
PNAS	NULL
is	NULL
available	NULL
online	NULL
at	NULL
www.pnas.org	NULL
.	NULL

11816	NULL
comparable	NULL
with	NULL
that	NULL
of	NULL
IgV	NULL
genes	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
9	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
raised	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
BCL-6	NULL
mutations	NULL
represent	NULL
a	NULL
tumor	NULL
associated	NULL
misfunction	NULL
or	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
IgV	NULL
hypermutation	NULL
process	NULL
acting	NULL
on	NULL
non-Ig	NULL
genes	NULL
.	NULL

To	NULL
address	NULL
this	NULL
issue	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
presence	NULL
of	NULL
BCL-6	NULL
mutations	NULL
in	NULL
normal	NULL
GC	NULL
and	NULL
naive	NULL
B	NULL
cells	NULL
by	NULL
PCR	NULL
amplification	NULL
and	NULL
direct	NULL
sequencing	NULL
of	NULL
DNA	NULL
from	NULL
single	NULL
cells	NULL
.	NULL

This	NULL
approach	NULL
allows	NULL
the	NULL
analysis	NULL
of	NULL
multiple	NULL
genes	NULL
and	NULL
alleles	NULL
from	NULL
a	NULL
specific	NULL
cell	NULL
,	NULL
eliminating	NULL
Taq	NULL
polymerase-mediated	NULL
misincorporations	NULL
(	NULL
21	NULL
)	NULL
.	NULL

We	NULL
also	NULL
have	NULL
analyzed	NULL
BCL-6	NULL
and	NULL
Ig	NULL
heavy-chain	NULL
V	NULL
(	NULL
Ig	NULL
Vy	NULL
)	NULL
mutations	NULL
in	NULL
B	NULL
cell	NULL
lymphomas	NULL
representative	NULL
of	NULL
various	NULL
stages	NULL
of	NULL
B	NULL
cell	NULL
development	NULL
,	NULL
including	NULL
GC	NULL
,	NULL
pre-	NULL
and	NULL
post-GC	NULL
stages	NULL
.	NULL

The	NULL
results	NULL
demonstrate	NULL
that	NULL
BCL-6	NULL
mutations	NULL
,	NULL
like	NULL
IgV	NULL
mutations	NULL
,	NULL
are	NULL
found	NULL
in	NULL
normal	NULL
GC	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
their	NULL
GC	NULL
and	NULL
post-GC	NULL
neoplastic	NULL
counter-parts	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
the	NULL
somatic	NULL
hypermutation	NULL
mechanism	NULL
affecting	NULL
Ig	NULL
genes	NULL
can	NULL
physiologically	NULL
target	NULL
non-Ig	NULL
sequences	NULL
,	NULL
with	NULL
implications	NULL
for	NULL
normal	NULL
B	NULL
cell	NULL
development	NULL
and	NULL
lymphomagenesis	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Tissue	NULL
Samples	NULL
.	NULL

Tumor	NULL
biopsies	NULL
from	NULL
341	NULL
patients	NULL
were	NULL
collected	NULL
during	NULL
standard	NULL
diagnostic	NULL
procedures	NULL
based	NULL
on	NULL
morphologic	NULL
,	NULL
immunophenotypic	NULL
,	NULL
and	NULL
cytogenetic	NULL
analysis	NULL
.	NULL

The	NULL
fraction	NULL
of	NULL
neoplastic	NULL
cells	NULL
corresponded	NULL
to	NULL
>	NULL
70	NULL
%	NULL
in	NULL
non-Hodgkin	NULL
lymphoma	NULL
cases	NULL
and	NULL
at	NULL
least	NULL
30	NULL
%	NULL
in	NULL
multiple	NULL
myeloma	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
13	NULL
Burkitt	NULL
lymphoma	NULL
(	NULL
BL	NULL
)	NULL
cell	NULL
lines	NULL
were	NULL
included	NULL
in	NULL
the	NULL
panel	NULL
.	NULL

Genomic	NULL
DNA	NULL
was	NULL
prepared	NULL
by	NULL
the	NULL
salting-out	NULL
procedure	NULL
.	NULL

For	NULL
the	NULL
single-cell	NULL
study	NULL
,	NULL
a	NULL
reactive	NULL
tonsil	NULL
from	NULL
a	NULL
S-year-old	NULL
child	NULL
and	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
of	NULL
an	NULL
unrelated	NULL
donor	NULL
were	NULL
used	NULL
.	NULL

Cell	NULL
Separation	NULL
and	NULL
Flow	NULL
Cytometry	NULL
.	NULL

The	NULL
protocol	NULL
for	NULL
purification	NULL
of	NULL
single	NULL
tonsillar	NULL
CD38+CD77+	NULL
and	NULL
CD38+CD77-	NULL
GC	NULL
B	NULL
cells	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
22	NULL
)	NULL
.	NULL

For	NULL
the	NULL
isolation	NULL
of	NULL
single	NULL
IgD+CD27-	NULL
B	NULL
cells	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
a	NULL
healthy	NULL
donor	NULL
,	NULL
mononuclear	NULL
cells	NULL
were	NULL
separated	NULL
by	NULL
Ficoll-Isopaque	NULL
density	NULL
centrifugation	NULL
,	NULL
and	NULL
CD19+	NULL
B	NULL
cells	NULL
were	NULL
purified	NULL
to	NULL
>	NULL
98	NULL
%	NULL
by	NULL
magnetic	NULL
cell	NULL
separation	NULL
by	NULL
using	NULL
the	NULL
MiniMACS	NULL
system	NULL
(	NULL
Miltenyi	NULL
Biotech	NULL
,	NULL
Bergisch	NULL
Gladbach	NULL
,	NULL
Germany	NULL
)	NULL
as	NULL
described	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
B	NULL
cell-enriched	NULL
cell	NULL
suspension	NULL
was	NULL
preincubated	NULL
for	NULL
5	NULL
'	NULL
with	NULL
1	NULL
mg/ml	NULL
Beriglobin	NULL
(	NULL
Ber-ingwerke	NULL
,	NULL
Marburg	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
a	NULL
human	NULL
Ig-fraction	NULL
,	NULL
followed	NULL
by	NULL
15	NULL
``	NULL
with	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
isomer	NULL
1	NULL
)	NULL
-conjugated	NULL
anti-CD27	NULL
and	NULL
biotinylated	NULL
goat	NULL
anti-human	NULL
(	NULL
GaH	NULL
)	NULL
-IgD	NULL
.	NULL

Af-	NULL
Abbreviations	NULL
:	NULL
BCL	NULL
,	NULL
B	NULL
Cell	NULL
Lymphoma	NULL
;	NULL
GC	NULL
,	NULL
germinal	NULL
center	NULL
;	NULL
IgV	NULL
,	NULL
variable	NULL
region	NULL
of	NULL
Ig	NULL
;	NULL
IgV	NULL
»	NULL
,	NULL
Ig	NULL
heavy-chain	NULL
V	NULL
;	NULL
SSCP	NULL
,	NULL
single	NULL
strand	NULL
conformation	NULL
polymorphism	NULL
;	NULL
CLL	NULL
,	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
;	NULL
DLCL	NULL
,	NULL
diffuse	NULL
large	NULL
cell	NULL
lymphoma	NULL
;	NULL
FL	NULL
,	NULL
follicular	NULL
lymphoma	NULL
;	NULL
BL	NULL
,	NULL
Burkitt	NULL
lymphoma	NULL
.	NULL

These	NULL
authors	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
article	NULL
.	NULL

``	NULL
To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

e-mail	NULL
:	NULL
rd10	NULL
@	NULL
columbia.edu	NULL
.	NULL

Immunology	NULL
:	NULL
Pasqualuceci	NULL
et	NULL
al	NULL
.	NULL

ter	NULL
washing	NULL
and	NULL
an	NULL
additional	NULL
5	NULL
'	NULL
incubation	NULL
with	NULL
Beriglobin	NULL
,	NULL
the	NULL
cell	NULL
suspension	NULL
was	NULL
stained	NULL
with	NULL
digoxygenated	NULL
antifluo-rescein	NULL
isothiocyanate-isomer	NULL
1	NULL
,	NULL
washed	NULL
twice	NULL
,	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
with	NULL
fluorescein	NULL
isothiocyanate-containing	NULL
anti-Digoxigenin	NULL
liposomes	NULL
(	NULL
24	NULL
)	NULL
for	NULL
30	NULL
'	NULL
under	NULL
constant	NULL
agitation	NULL
.	NULL

Single	NULL
IgD+CD27-	NULL
B	NULL
cells	NULL
were	NULL
sorted	NULL
on	NULL
a	NULL
FACS	NULL
440	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
directly	NULL
into	NULL
PCR	NULL
tubes	NULL
containing	NULL
20	NULL
pul	NULL
of	NULL
1X	NULL
Expand	NULL
High	NULL
Fidelity	NULL
PCR	NULL
buffer	NULL
(	NULL
Boehringer	NULL
Mann-heim	NULL
)	NULL
and	NULL
1	NULL
ng/ul	NULL
58	NULL
rRNA	NULL
.	NULL

Single-Cell	NULL
PCR	NULL
.	NULL

Single	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
0.25	NULL
mg/ml	NULL
proteinase	NULL
K	NULL
for	NULL
1	NULL
h	NULL
at	NULL
50°C	NULL
,	NULL
followed	NULL
by	NULL
10	NULL
'	NULL
at	NULL
95°C	NULL
for	NULL
inactivation	NULL
of	NULL
the	NULL
enzyme	NULL
.	NULL

A	NULL
seminested	NULL
multiplex	NULL
PCR	NULL
strategy	NULL
was	NULL
devised	NULL
to	NULL
simultaneously	NULL
amplify	NULL
the	NULL
rearranged	NULL
Ig	NULL
V3	NULL
genes	NULL
of	NULL
the	NULL
largest	NULL
V1	NULL
,	NULL
V3	NULL
,	NULL
and	NULL
Vy4	NULL
families	NULL
,	NULL
along	NULL
with	NULL
the	NULL
BCL-6	NULL
first	NULL
intron	NULL
(	NULL
742	NULL
bp	NULL
)	NULL
and	NULL
a	NULL
394-bp	NULL
genomic	NULL
region	NULL
of	NULL
the	NULL
-globin	NULL
gene	NULL
,	NULL
spanning	NULL
exon1/intron1/exon2	NULL
.	NULL

For	NULL
the	NULL
first	NULL
round	NULL
of	NULL
amplification	NULL
,	NULL
a	NULL
total	NULL
number	NULL
of	NULL
eight	NULL
gel-purified	NULL
oligonucleotides	NULL
(	NULL
10	NULL
when	NULL
the	NULL
B-globin	NULL
was	NULL
co-amplified	NULL
)	NULL
were	NULL
used	NULL
in	NULL
the	NULL
same	NULL
reaction	NULL
mix	NULL
.	NULL

The	NULL
Vy	NULL
family-specific	NULL
and	NULL
3	NULL
'	NULL
antisense	NULL
J	NULL
;	NULL
primers	NULL
have	NULL
been	NULL
described	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Sequences	NULL
of	NULL
the	NULL
oligonucleotides	NULL
for	NULL
amplification	NULL
of	NULL
the	NULL
BCL-6	NULL
and	NULL
B-globin	NULL
genes	NULL
are	NULL
available	NULL
on	NULL
request	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
each	NULL
primer	NULL
pair	NULL
was	NULL
titrated	NULL
in	NULL
a	NULL
PCR	NULL
assay	NULL
and	NULL
varied	NULL
considerably	NULL
among	NULL
the	NULL
loci	NULL
to	NULL
allow	NULL
concurrent	NULL
amplification	NULL
of	NULL
multiple	NULL
target	NULL
genes	NULL
(	NULL
8.4	NULL
nM	NULL
for	NULL
the	NULL
V	NULL
and	NULL
Jy	NULL
primers	NULL
;	NULL
100	NULL
nM	NULL
each	NULL
BCL-6	NULL
primer	NULL
and	NULL
50	NULL
nM	NULL
each	NULL
-globin	NULL
primer	NULL
)	NULL
.	NULL

The	NULL
PCR	NULL
conditions	NULL
for	NULL
the	NULL
first	NULL
round	NULL
of	NULL
amplification	NULL
have	NULL
been	NULL
reported	NULL
(	NULL
21	NULL
)	NULL
.	NULL

For	NULL
the	NULL
second	NULL
round	NULL
of	NULL
amplification	NULL
,	NULL
a	NULL
1.5-pl	NULL
aliquot	NULL
of	NULL
the	NULL
first	NULL
reaction	NULL
mix	NULL
was	NULL
used	NULL
as	NULL
template	NULL
in	NULL
separate	NULL
reactions	NULL
for	NULL
each	NULL
of	NULL
the	NULL
five	NULL
loci	NULL
analyzed	NULL
.	NULL

The	NULL
antisense	NULL
oligonucleotides	NULL
were	NULL
replaced	NULL
by	NULL
internal	NULL
primers	NULL
,	NULL
and	NULL
the	NULL
reaction	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
volume	NULL
containing	NULL
Expand	NULL
High	NULL
Fidelity	NULL
buffer	NULL
,	NULL
1.5	NULL
mM	NULL
MgC	NULL
]	NULL
;	NULL
,	NULL
200	NULL
wM	NULL
each	NULL
dNTP	NULL
,	NULL
200	NULL
nM	NULL
each	NULL
BCL-6	NULL
or	NULL
B-globin	NULL
primer	NULL
,	NULL
125	NULL
nM	NULL
for	NULL
the	NULL
pairs	NULL
,	NULL
and	NULL
2.5	NULL
units	NULL
Taq	NULL
DNA	NULL
polymerase	NULL
.	NULL

Cycling	NULL
conditions	NULL
were	NULL
the	NULL
following	NULL
:	NULL
for	NULL
the	NULL
B-globin	NULL
gene	NULL
,	NULL
95°C	NULL
for	NULL
5	NULL
,	NULL
65°C	NULL
for	NULL
4	NULL
``	NULL
,	NULL
72°C	NULL
for	NULL
1	NULL
``	NULL
,	NULL
followed	NULL
by	NULL
29	NULL
cycles	NULL
at	NULL
95°C	NULL
for	NULL
1	NULL
``	NULL
,	NULL
63°C	NULL
for	NULL
30	NULL
``	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
1	NULL
'	NULL
.	NULL

For	NULL
the	NULL
BCL-6	NULL
gene	NULL
,	NULL
95°C	NULL
for	NULL
5	NULL
,	NULL
followed	NULL
by	NULL
30	NULL
cycles	NULL
at	NULL
95°C	NULL
for	NULL
30	NULL
``	NULL
,	NULL
57°C	NULL
for	NULL
30	NULL
``	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
45	NULL
``	NULL
.	NULL

Programs	NULL
ended	NULL
with	NULL
a	NULL
final	NULL
step	NULL
at	NULL
72°C	NULL
for	NULL
7	NULL
'	NULL
.	NULL

The	NULL
protocol	NULL
for	NULL
single	NULL
cell	NULL
reamplification	NULL
of	NULL
V	NULL
;	NULL
genes	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
22	NULL
)	NULL
.	NULL

To	NULL
avoid	NULL
contamination	NULL
by	NULL
DNA	NULL
throughout	NULL
the	NULL
procedure	NULL
,	NULL
separate	NULL
working	NULL
areas	NULL
were	NULL
designated	NULL
for	NULL
pre-	NULL
and	NULL
post-PCR	NULL
manipulations	NULL
,	NULL
and	NULL
negative	NULL
water	NULL
controls	NULL
were	NULL
included	NULL
for	NULL
every	NULL
cell	NULL
in	NULL
all	NULL
the	NULL
experiments	NULL
(	NULL
r	NULL
=	NULL
200	NULL
)	NULL
.	NULL

Cloning	NULL
Procedure	NULL
.	NULL

Cloning	NULL
into	NULL
pGEM-T	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
was	NULL
required	NULL
for	NULL
confirmation	NULL
of	NULL
BCL-6	NULL
mutations	NULL
in	NULL
two	NULL
tumor	NULL
cases	NULL
as	NULL
well	NULL
as	NULL
in	NULL
those	NULL
cells	NULL
in	NULL
which	NULL
the	NULL
occurrence	NULL
of	NULL
insertions/deletions	NULL
in	NULL
heterozygosis	NULL
induced	NULL
a	NULL
frameshift	NULL
,	NULL
preventing	NULL
evaluation	NULL
of	NULL
the	NULL
downstream	NULL
sequences	NULL
.	NULL

Ligated	NULL
PCR	NULL
products	NULL
were	NULL
transformed	NULL
into	NULL
DHS	NULL
@	NULL
competent	NULL
cells	NULL
and	NULL
at	NULL
least	NULL
four	NULL
clones/reaction	NULL
were	NULL
sequenced	NULL
.	NULL

Sequencing	NULL
Analysis	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
purified	NULL
by	NULL
using	NULL
the	NULL
Wizard	NULL
PCR	NULL
Preps	NULL
kit	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
directly	NULL
sequenced	NULL
from	NULL
both	NULL
strands	NULL
by	NULL
using	NULL
the	NULL
same	NULL
primers	NULL
as	NULL
in	NULL
the	NULL
second	NULL
amplification	NULL
reaction	NULL
,	NULL
with	NULL
two	NULL
additional	NULL
internal	NULL
oligonucleotides	NULL
for	NULL
the	NULL
larger	NULL
BCL-6	NULL
product	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
procedure	NULL
was	NULL
accomplished	NULL
by	NULL
the	NULL
dideoxy	NULL
chain	NULL
termination	NULL
method	NULL
on	NULL
a	NULL
ABI373A	NULL
sequencer	NULL
(	NULL
Perkin-Elmer	NULL
,	NULL
Applied	NULL
Biosystems	NULL
)	NULL
.	NULL

Sequencing	NULL
analysis	NULL
and	NULL
alignments	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
the	NULL
GCG	NULL
package	NULL
(	NULL
Genetics	NULL
Computer	NULL
Group	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
and	NULL
the	NULL
GenBank	NULL
data	NULL
library	NULL
as	NULL
well	NULL
as	NULL
DNAPLOT	NULL
(	NULL
www	NULL
.	NULL

genetik.uni-koeln.de	NULL
)	NULL
for	NULL
comparison	NULL
of	NULL
the	NULL
rearranged	NULL
IgV	NULL
genes	NULL
to	NULL
the	NULL
most	NULL
homologous	NULL
germline	NULL
sequences	NULL
.	NULL

Ig	NULL
Vx	NULL
amplicons	NULL
representing	NULL
either	NULL
non-Ig	NULL
sequences	NULL
(	NULL
r	NULL
=	NULL
2	NULL
)	NULL
or	NULL
double	NULL
sequences	NULL
(	NULL
as	NULL
in	NULL
case	NULL
both	NULL
alleles	NULL
are	NULL
rearranged	NULL
by	NULL
using	NULL
the	NULL
same	NULL
Vy	NULL
family	NULL
)	NULL
were	NULL
not	NULL
considered	NULL
for	NULL
analysis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
(	NULL
1998	NULL
)	NULL
-	NULL
11817	NULL
Single	NULL
Strand	NULL
Conformation	NULL
Polymorphism	NULL
(	NULL
SSCP	NULL
)	NULL
Analysis	NULL
and	NULL
Sequencing	NULL
of	NULL
Tumor	NULL
Samples	NULL
.	NULL

SSCP	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
reported	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

For	NULL
sequencing	NULL
of	NULL
the	NULL
BCL-6	NULL
5'-noncoding	NULL
region	NULL
,	NULL
a	NULL
unique	NULL
PCR	NULL
product	NULL
was	NULL
generated	NULL
from	NULL
100	NULL
ng	NULL
of	NULL
genomic	NULL
DNA	NULL
by	NULL
using	NULL
the	NULL
same	NULL
primers	NULL
and	NULL
conditions	NULL
as	NULL
in	NULL
the	NULL
second	NULL
round	NULL
of	NULL
amplification	NULL
of	NULL
the	NULL
single-cell	NULL
PCR	NULL
.	NULL

The	NULL
protocol	NULL
for	NULL
amplification	NULL
/sequencing	NULL
of	NULL
rearranged	NULL
IgV	NULL
;	NULL
genes	NULL
is	NULL
described	NULL
in	NULL
ref	NULL
.	NULL

25	NULL
.	NULL

All	NULL
Vy	NULL
primers	NULL
in	NULL
this	NULL
study	NULL
hybridize	NULL
to	NULL
sequences	NULL
in	NULL
the	NULL
framework	NULL
region	NULL
I	NULL
of	NULL
the	NULL
respective	NULL
Vy	NULL
families	NULL
.	NULL

RESULTS	NULL
BCL-6	NULL
Mutations	NULL
in	NULL
Normal	NULL
GC	NULL
B	NULL
Cells	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
normal	NULL
B	NULL
cells	NULL
display	NULL
mutations	NULL
in	NULL
their	NULL
BCL-6	NULL
gene	NULL
,	NULL
human	NULL
B	NULL
cell	NULL
populations	NULL
corresponding	NULL
to	NULL
GC	NULL
centroblasts	NULL
(	NULL
CD38+CD77+	NULL
)	NULL
and	NULL
centrocytes	NULL
(	NULL
CD38+CD77-	NULL
)	NULL
as	NULL
well	NULL
as	NULL
naive	NULL
B	NULL
cells	NULL
(	NULL
sIgD+	NULL
CD27-	NULL
)	NULL
were	NULL
isolated	NULL
individually	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
from	NULL
a	NULL
reactive	NULL
tonsil	NULL
and	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
healthy	NULL
donors	NULL
.	NULL

In	NULL
these	NULL
cells	NULL
,	NULL
we	NULL
analyzed	NULL
a	NULL
BCL-6	NULL
742-bp	NULL
genomic	NULL
region	NULL
previously	NULL
shown	NULL
to	NULL
represent	NULL
the	NULL
major	NULL
cluster	NULL
of	NULL
mutations	NULL
in	NULL
DLCL	NULL
and	NULL
FL	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Using	NULL
a	NULL
multiplex	NULL
seminested	NULL
single-cell	NULL
PCR	NULL
approach	NULL
,	NULL
we	NULL
generated	NULL
amplicons	NULL
from	NULL
the	NULL
BCL-6	NULL
intron	NULL
1	NULL
and	NULL
the	NULL
rearranged	NULL
IgV	NULL
;	NULL
genes	NULL
of	NULL
the	NULL
same	NULL
cell	NULL
and	NULL
analyzed	NULL
them	NULL
by	NULL
direct	NULL
sequencing	NULL
.	NULL

In	NULL
a	NULL
subset	NULL
(	NULL
n	NULL
=	NULL
36	NULL
)	NULL
of	NULL
the	NULL
cells	NULL
,	NULL
the	NULL
nontranscribed	NULL
B-globin	NULL
gene	NULL
was	NULL
coamplified	NULL
and	NULL
sequenced	NULL
as	NULL
a	NULL
control	NULL
for	NULL
locus	NULL
specificity	NULL
of	NULL
the	NULL
mutations	NULL
.	NULL

The	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
BCL-6	NULL
gene	NULL
is	NULL
altered	NULL
by	NULL
somatic	NULL
mutations	NULL
in	NULL
~30	NULL
%	NULL
GC	NULL
lymphocytes	NULL
but	NULL
not	NULL
in	NULL
naive	NULL
B	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
frequency	NULL
of	NULL
mutated	NULL
cells	NULL
were	NULL
observed	NULL
between	NULL
the	NULL
two	NULL
GC-derived	NULL
subpopulations	NULL
,	NULL
centroblasts	NULL
and	NULL
centrocytes	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
mutated	NULL
GC	NULL
cells	NULL
most	NULL
likely	NULL
represents	NULL
an	NULL
underestimate	NULL
because	NULL
only	NULL
one	NULL
allele	NULL
could	NULL
be	NULL
amplified	NULL
in	NULL
43	NULL
%	NULL
(	NULL
50/116	NULL
)	NULL
of	NULL
the	NULL
cells	NULL
analyzed	NULL
.	NULL

The	NULL
allelic	NULL
status	NULL
could	NULL
be	NULL
assessed	NULL
based	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
three	NULL
linked	NULL
polymorphisms	NULL
[	NULL
two	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
)	NULL
and	NULL
a	NULL
G/A	NULL
substitution	NULL
in	NULL
position	NULL
+858	NULL
]	NULL
occurring	NULL
in	NULL
heterozygosis	NULL
in	NULL
the	NULL
subject	NULL
investigated	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Sequencing	NULL
analysis	NULL
of	NULL
BCL-6	NULL
amplicons	NULL
in	NULL
centroblasts	NULL
and	NULL
centrocytes	NULL
revealed	NULL
a	NULL
frequency	NULL
of	NULL
mutations	NULL
of	NULL
0.07	NULL
and	NULL
0.04	NULL
x	NULL
10-2/bp	NULL
,	NULL
respectively	NULL
(	NULL
range	NULL
:	NULL
0-0.4	NULL
x	NULL
10-/bp	NULL
,	NULL
corresponding	NULL
to	NULL
0-3	NULL
mutations	NULL
per	NULL
allele	NULL
)	NULL
.	NULL

This	NULL
frequency	NULL
was	NULL
significantly	NULL
higher	NULL
than	NULL
that	NULL
observed	NULL
in	NULL
naive	NULL
B	NULL
cells	NULL
(	NULL
0.009	NULL
x	NULL
10-2/bp	NULL
;	NULL
P	NULL
=	NULL
0.01	NULL
)	NULL
,	NULL
which	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
was	NULL
indistinguishable	NULL
from	NULL
the	NULL
Taq	NULL
misincorporation	NULL
rate	NULL
(	NULL
see	NULL
results	NULL
of	NULL
the	NULL
B-globin	NULL
analysis	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
average	NULL
frequency	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
Ig	NULL
V	NULL
,	NULL
;	NULL
genes	NULL
from	NULL
GC	NULL
B	NULL
cells	NULL
was	NULL
~5	NULL
X	NULL
10-*/bp	NULL
,	NULL
whereas	NULL
most	NULL
naive	NULL
B	NULL
cells	NULL
displayed	NULL
Vy	NULL
sequences	NULL
in	NULL
germline	NULL
configuration	NULL
,	NULL
as	NULL
expected	NULL
(	NULL
4	NULL
,	NULL
23	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
2	NULL
Vp-mutated	NULL
cells	NULL
most	NULL
likely	NULL
represented	NULL
accidentally	NULL
sorted	NULL
non-naive	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
BCL-6	NULL
sequences	NULL
could	NULL
not	NULL
be	NULL
analyzed	NULL
in	NULL
these	NULL
cases	NULL
because	NULL
a	NULL
positive	NULL
PCR	NULL
product	NULL
was	NULL
not	NULL
obtained	NULL
.	NULL

The	NULL
B-globin	NULL
gene	NULL
,	NULL
successfully	NULL
amplified	NULL
in	NULL
32/36	NULL
centroblasts	NULL
,	NULL
was	NULL
consistently	NULL
found	NULL
unmutated	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
a	NULL
cell-specific	NULL
,	NULL
locus-specific	NULL
hypermutation	NULL
mechanism	NULL
targets	NULL
BCL-6	NULL
sequences	NULL
in	NULL
normal	NULL
GC	NULL
cells	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
mutations	NULL
appeared	NULL
to	NULL
be	NULL
10-	NULL
to	NULL
100-fold	NULL
lower	NULL
than	NULL
that	NULL
observed	NULL
in	NULL
rearranged	NULL
IgV	NULL
;	NULL
genes	NULL
from	NULL
the	NULL
same	NULL
cells	NULL
.	NULL

BCL-6	NULL
Mutations	NULL
are	NULL
Restricted	NULL
to	NULL
Neoplasms	NULL
Derived	NULL
from	NULL
GC	NULL
or	NULL
Post-GC	NULL
Cells	NULL
and	NULL
Carrying	NULL
IgVy	NULL
Mutations	NULL
.	NULL

To	NULL
corroborate	NULL
the	NULL
specific	NULL
association	NULL
among	NULL
BCL-6	NULL
mutations	NULL
,	NULL
IgV	NULL
mutations	NULL
,	NULL
and	NULL
GC	NULL
transit	NULL
,	NULL
we	NULL
screened	NULL
for	NULL
BCL-6	NULL
and	NULL
Ig	NULL
Vx	NULL
mutations	NULL
a	NULL
panel	NULL
of	NULL
B	NULL
cell	NULL
tumors	NULL
representative	NULL
of	NULL
various	NULL
stages	NULL
of	NULL
B	NULL
cell	NULL
differentiation	NULL
,	NULL
including	NULL
pre-B	NULL
cells	NULL
(	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
:	NULL
ALL	NULL
)	NULL
,	NULL
pre-GC	NULL
(	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
)	NULL
(	NULL
27	NULL
)	NULL
,	NULL
GC-	NULL
(	NULL
DLCL	NULL
,	NULL
FL	NULL
,	NULL
BL	NULL
)	NULL
and	NULL
post	NULL
GC-	NULL
(	NULL
multiple	NULL
myeloma	NULL
:	NULL
MM	NULL
)	NULL
derived	NULL
tumors	NULL
.	NULL

Thirty-three	NULL
cases	NULL
of	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
(	NULL
CLL	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
harbor	NULL
11818	NULL
_	NULL
Immunology	NULL
:	NULL
Pasqualucci	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
(	NULL
1998	NULL
)	NULL
+400	NULL
p	NULL
424	NULL
444	NULL
464	NULL
484	NULL
Sos	NULL
she	NULL
see	NULL
Sea	NULL
Sha	NULL
604	NULL
Gat	NULL
G44	NULL
64	NULL
bmi	NULL
704	NULL
Tar	NULL
Par	NULL
Toi	NULL
Tea	NULL
60	NULL
%	NULL
Bat	NULL
Sad	NULL
Bor	NULL
904	NULL
Sea	NULL
gas	NULL
gor	NULL
98d	NULL
1004	NULL
1024	NULL
tose	NULL
i06a	NULL
1084	NULL
1104	NULL
1124	NULL
144	NULL
,	NULL
mutation	NULL
(	NULL
position	NULL
)	NULL
F	NULL
1	NULL
ecti7*	NULL
T451G	NULL
;	NULL
T470G	NULL
celds	NULL
Tasso	NULL
ee120	NULL
G	NULL
&	NULL
70A	NULL
cel55	NULL
Gst1C	NULL
,	NULL
cute	NULL
corse	NULL
Teo	NULL
«	NULL
G	NULL
cetsd	NULL
CsorA	NULL
;	NULL
C749G	NULL
wccl3i*	NULL
Té2SG	NULL
;	NULL
CBOSG	NULL
;	NULL
Ta3eG	NULL
w	NULL
fect73	NULL
Gesso	NULL
£	NULL
.	NULL

|ect26®	NULL
ases-7i0	NULL
>	NULL
[	NULL
clade	NULL
G770A	NULL
;	NULL
G1015A	NULL
Tosa	NULL
Ofccisor	NULL
Creat	NULL
;	NULL
T7gza	NULL
;	NULL
coret	NULL
;	NULL
G10sec	NULL
ac	NULL
fect37	NULL
Crest	NULL
i-	NULL
[	NULL
ectL1*	NULL
C791T	NULL
;	NULL
T1009A	NULL
a	NULL
Great	NULL
wfect49	NULL
CB24G	NULL
;	NULL
Gesst	NULL
eer30®	NULL
Asseo	NULL
~	NULL
GareA	NULL
;	NULL
Carse	NULL
cei7s	NULL
al	NULL
eelst	NULL
TosrC	NULL
cet76	NULL
A9csG	NULL
-	NULL
A	NULL
A968	NULL
-	NULL
agree	NULL
leet	NULL
14	NULL
-	NULL
=	NULL
i	NULL
-	NULL
-	NULL
-	NULL
--	NULL
--	NULL
-	NULL
on	NULL
on	NULL
on	NULL
n	NULL
n	NULL
n	NULL
n	NULL
ne	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
en	NULL
n	NULL
n	NULL
owe	NULL
en	NULL
en	NULL
en	NULL
en	NULL
n	NULL
croost	NULL
49	NULL
[	NULL
eBR	NULL
-	NULL
m	NULL
n	NULL
nn	NULL
ws	NULL
on	NULL
n	NULL
n	NULL
nwn	NULL
nn	NULL
n	NULL
ne	NULL
n	NULL
n	NULL
e	NULL
n	NULL
n	NULL
n	NULL
e	NULL
n	NULL
we	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
e	NULL
en	NULL
en	NULL
en	NULL
e	NULL
Taasc	NULL
;	NULL
Csean	NULL
;	NULL
Grsea	NULL
be	NULL
=	NULL
=-	NULL
<	NULL
n	NULL
sen	NULL
on	NULL
owe	NULL
on	NULL
on	NULL
on	NULL
on	NULL
nn	NULL
ns	NULL
-o	NULL
»	NULL
-	NULL
-	NULL
--	NULL
-	NULL
-=	NULL
<	NULL
--	NULL
-	NULL
-	NULL
mn	NULL
ees	NULL
AS10T	NULL
;	NULL
th	NULL
.	NULL

o=	NULL
-	NULL
n	NULL
n	NULL
n	NULL
n	NULL
ng	NULL
nn	NULL
eee	NULL
on	NULL
on	NULL
on	NULL
on	NULL
on	NULL
on	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
22	NULL
22	NULL
_	NULL
caree	NULL
;	NULL
tsriG	NULL
;	NULL
tsrgc	NULL
=	NULL
=	NULL
nes	NULL
n	NULL
n	NULL
n	NULL
n	NULL
nee	NULL
n	NULL
-	NULL
o	NULL
oe	NULL
n	NULL
n	NULL
se	NULL
-	NULL
-	NULL
-	NULL
-	NULL
enn	NULL
n	NULL
n	NULL
nen	NULL
en	NULL
en	NULL
en	NULL
en	NULL
e	NULL
e	NULL
-	NULL
Tss2c	NULL
;	NULL
Asses	NULL
;	NULL
caose	NULL
-a	NULL
fth628	NULL
-	NULL
=	NULL
on	NULL
n	NULL
on	NULL
nem	NULL
ue	NULL
eg	NULL
on	NULL
on	NULL
on	NULL
owe	NULL
on	NULL
on	NULL
n	NULL
n	NULL
on	NULL
n	NULL
n	NULL
on	NULL
n	NULL
n	NULL
on	NULL
en	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
22	NULL
22	NULL
_	NULL
assse	NULL
;	NULL
a	NULL
--	NULL
<	NULL
m	NULL
n	NULL
on	NULL
on	NULL
on	NULL
n	NULL
n	NULL
on	NULL
ee	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
ege	NULL
n	NULL
n	NULL
n	NULL
n	NULL
ee	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
2	NULL
2	NULL
n	NULL
2	NULL
22	NULL
22	NULL
z	NULL
arsea	NULL
;	NULL
Cesat	NULL
;	NULL
Casar	NULL
.	NULL

-	NULL
n	NULL
n	NULL
nn	NULL
en	NULL
nn	NULL
n	NULL
en	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
ge	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
e	NULL
n	NULL
en	NULL
en	NULL
reac	NULL
it	NULL
ebd®	NULL
oo	NULL
s	NULL
-	NULL
n	NULL
n	NULL
n	NULL
en	NULL
--	NULL
noe	NULL
hn	NULL
en	NULL
en	NULL
en	NULL
e	NULL
e	NULL
n	NULL
en	NULL
en	NULL
ew	NULL
e	NULL
n	NULL
en	NULL
nwn	NULL
nn	NULL
Wn	NULL
nn	NULL
on	NULL
en	NULL
en	NULL
en	NULL
n	NULL
en	NULL
en	NULL
men	NULL
<	NULL
<	NULL
--	NULL
--	NULL
|	NULL
772A	NULL
;	NULL
ABEOG	NULL
;	NULL
GBBRA	NULL
;	NULL
A1Osec	NULL
i-	NULL
[	NULL
cbege	NULL
-	NULL
-	NULL
o	NULL
n	NULL
n	NULL
en	NULL
en	NULL
en	NULL
en	NULL
s	NULL
ee	NULL
e	NULL
ee	NULL
-	NULL
Coun	NULL
sen	NULL
en	NULL
>	NULL
>	NULL
-	NULL
-	NULL
en	NULL
en	NULL
ee	NULL
mn	NULL
en	NULL
en	NULL
en	NULL
en	NULL
en	NULL
nn	NULL
-	NULL
Tresc	NULL
at	NULL
folia	NULL
o	NULL
-	NULL
n	NULL
n	NULL
n	NULL
en	NULL
n	NULL
e	NULL
n	NULL
n	NULL
e	NULL
n	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
w	NULL
n	NULL
e	NULL
e	NULL
e	NULL
n	NULL
n	NULL
e	NULL
e	NULL
n	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
Grora	NULL
w	NULL
fehB8	NULL
.	NULL

--	NULL
o=	NULL
-	NULL
-	NULL
<	NULL
n	NULL
n	NULL
-	NULL
on	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
n	NULL
e	NULL
n	NULL
n	NULL
ge	NULL
n	NULL
n	NULL
n	NULL
ege	NULL
n	NULL
n	NULL
n	NULL
n	NULL
eee	NULL
n	NULL
n	NULL
n	NULL
22	NULL
22	NULL
22	NULL
_	NULL
TeseC	NULL
;	NULL
T1000	NULL
O	NULL
.	NULL

-	NULL
=	NULL
n	NULL
en	NULL
n	NULL
n	NULL
en	NULL
en	NULL
en	NULL
en	NULL
-	NULL
sss	NULL
ne	NULL
ie	NULL
se	NULL
>	NULL
wn	NULL
sees	NULL
hen	NULL
en	NULL
e	NULL
sen	NULL
n	NULL
ao	NULL
--	NULL
-	NULL
-	NULL
20	NULL
bp	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Distribution	NULL
of	NULL
mutations	NULL
within	NULL
the	NULL
BCL-6	NULL
5'-noncoding	NULL
sequences	NULL
of	NULL
37	NULL
single	NULL
GC	NULL
B	NULL
cells	NULL
.	NULL

(	NULL
Upper	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
BCL-6	NULL
gene	NULL
.	NULL

Coding	NULL
and	NULL
noncoding	NULL
exons	NULL
are	NULL
indicated	NULL
by	NULL
filled	NULL
and	NULL
empty	NULL
boxes	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
PCR	NULL
fragment	NULL
amplified	NULL
for	NULL
mutational	NULL
analysis	NULL
is	NULL
approximately	NULL
positioned	NULL
below	NULL
the	NULL
map	NULL
and	NULL
blown	NULL
up	NULL
in	NULL
the	NULL
lower	NULL
panel	NULL
to	NULL
show	NULL
the	NULL
distribution	NULL
of	NULL
mutations	NULL
.	NULL

Each	NULL
line	NULL
represents	NULL
a	NULL
20-bp	NULL
interval	NULL
of	NULL
the	NULL
BCL-6	NULL
sequence	NULL
amplified	NULL
,	NULL
and	NULL
the	NULL
first	NULL
nucleotide	NULL
of	NULL
the	NULL
BCL-6	NULL
cDNA	NULL
is	NULL
designated	NULL
as	NULL
position	NULL
+1	NULL
.	NULL

Mutations	NULL
included	NULL
single	NULL
base	NULL
pair	NULL
substitutions	NULL
(	NULL
closed	NULL
ovals	NULL
)	NULL
and	NULL
deletions	NULL
(	NULL
brackets	NULL
)	NULL
.	NULL

For	NULL
each	NULL
cell	NULL
,	NULL
identified	NULL
by	NULL
its	NULL
code	NULL
number	NULL
,	NULL
the	NULL
type	NULL
and	NULL
exact	NULL
position	NULL
of	NULL
the	NULL
mutation	NULL
are	NULL
specified	NULL
on	NULL
the	NULL
right	NULL
column	NULL
(	NULL
A	NULL
,	NULL
deletion	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
all	NULL
of	NULL
the	NULL
68	NULL
nucleotide	NULL
exchanges	NULL
,	NULL
including	NULL
deletions	NULL
,	NULL
were	NULL
found	NULL
in	NULL
heterozygosis	NULL
when	NULL
both	NULL
alleles	NULL
were	NULL
amplified	NULL
(	NULL
cells	NULL
marked	NULL
by	NULL
an	NULL
asterisk	NULL
)	NULL
.	NULL

mutated	NULL
IgV	NULL
genes	NULL
in	NULL
up	NULL
to	NULL
40	NULL
%	NULL
of	NULL
cases	NULL
(	NULL
28	NULL
)	NULL
,	NULL
also	NULL
were	NULL
included	NULL
in	NULL
the	NULL
panel	NULL
,	NULL
along	NULL
with	NULL
T	NULL
cell-derived	NULL
malignancies	NULL
and	NULL
non-lymphoid	NULL
malignancies	NULL
.	NULL

Because	NULL
tumors	NULL
reflect	NULL
the	NULL
clonal	NULL
history	NULL
of	NULL
their	NULL
cell	NULL
of	NULL
origin	NULL
,	NULL
we	NULL
postulated	NULL
that	NULL
if	NULL
BCL-6	NULL
and	NULL
IgV	NULL
sequences	NULL
were	NULL
targeted	NULL
by	NULL
the	NULL
same	NULL
mechanism	NULL
,	NULL
the	NULL
respective	NULL
frequency	NULL
and	NULL
distribution	NULL
of	NULL
mutations	NULL
should	NULL
correlate	NULL
in	NULL
the	NULL
various	NULL
histologic	NULL
categories	NULL
.	NULL

A	NULL
total	NULL
number	NULL
of	NULL
354	NULL
tumor	NULL
samples	NULL
was	NULL
investigated	NULL
for	NULL
BCL-6	NULL
mutations	NULL
by	NULL
SSCP	NULL
in	NULL
the	NULL
same	NULL
region	NULL
analyzed	NULL
in	NULL
normal	NULL
cells	NULL
.	NULL

Sequence	NULL
variants	NULL
were	NULL
found	NULL
at	NULL
significant	NULL
frequency	NULL
in	NULL
lymphoid	NULL
malignancies	NULL
derived	NULL
from	NULL
GC	NULL
(	NULL
DLCL	NULL
,	NULL
FL	NULL
,	NULL
BL	NULL
)	NULL
,	NULL
post-GC	NULL
(	NULL
MM	NULL
)	NULL
,	NULL
and	NULL
CD5S+	NULL
B	NULL
cells	NULL
(	NULL
CLL	NULL
)	NULL
,	NULL
but	NULL
not	NULL
from	NULL
pre-B	NULL
cells	NULL
(	NULL
0/19	NULL
ALL	NULL
)	NULL
or	NULL
pre-GC	NULL
B	NULL
cells	NULL
(	NULL
1/19	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
)	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Two	NULL
of	NULL
15	NULL
(	NULL
13	NULL
%	NULL
)	NULL
peripheral	NULL
T	NULL
cell	NULL
lymphomas	NULL
also	NULL
displayed	NULL
an	NULL
altered	NULL
migration	NULL
pattern	NULL
upon	NULL
SSCP	NULL
analysis	NULL
;	NULL
the	NULL
occurrence	NULL
of	NULL
BCL-6	NULL
mutations	NULL
in	NULL
these	NULL
Table	NULL
1.	NULL
cases	NULL
may	NULL
reflect	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
somatic	NULL
hypermutation	NULL
mechanism	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
within	NULL
the	NULL
GC	NULL
,	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
these	NULL
cells	NULL
accumulate	NULL
mutations	NULL
in	NULL
their	NULL
T	NULL
cell	NULL
receptor	NULL
a	NULL
and	NULL
B	NULL
V	NULL
genes	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

This	NULL
possibility	NULL
could	NULL
not	NULL
be	NULL
tested	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
material	NULL
from	NULL
these	NULL
particular	NULL
cases	NULL
.	NULL

No	NULL
BCL-6	NULL
mutations	NULL
were	NULL
found	NULL
in	NULL
non-lymphoid	NULL
malignancies	NULL
,	NULL
which	NULL
lack	NULL
Ig	NULL
Vy	NULL
mutations	NULL
.	NULL

To	NULL
comparatively	NULL
examine	NULL
the	NULL
frequency	NULL
and	NULL
type	NULL
of	NULL
mutations	NULL
occurring	NULL
in	NULL
the	NULL
BCL-6	NULL
and	NULL
Ig	NULL
V	NULL
,	NULL
genes	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
mutated	NULL
sequences	NULL
in	NULL
a	NULL
subset	NULL
of	NULL
cases	NULL
representative	NULL
of	NULL
the	NULL
main	NULL
categories	NULL
of	NULL
B	NULL
cell	NULL
lymphomas	NULL
,	NULL
including	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
,	NULL
CLL	NULL
,	NULL
BL	NULL
,	NULL
FL	NULL
,	NULL
DLCL	NULL
,	NULL
and	NULL
MM	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
BCL-6	NULL
and	NULL
IgVy	NULL
mutations	NULL
correlated	NULL
in	NULL
different	NULL
tumor	NULL
subtypes	NULL
,	NULL
with	NULL
BCL-6	NULL
substitutions	NULL
being	NULL
consistently	NULL
lower	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
both	NULL
genes	NULL
,	NULL
mutations	NULL
were	NULL
specifically	NULL
associated	NULL
with	NULL
GC-transit	NULL
;	NULL
this	NULL
was	NULL
particularly	NULL
evident	NULL
in	NULL
CLL	NULL
cases	NULL
,	NULL
in	NULL
Single	NULL
cell	NULL
analysis	NULL
of	NULL
the	NULL
BCL-6	NULL
and	NULL
Ig	NULL
Vy	NULL
genes	NULL
in	NULL
normal	NULL
GC	NULL
lymphocytes	NULL
Mutated	NULL
cells	NULL
,	NULL
%	NULL
*	NULL
Mutations	NULL
,	NULL
%	NULL
t	NULL
Cell	NULL
phenotype	NULL
BCL-6	NULL
B-globin	NULL
BCL-6	NULL
(	NULL
742	NULL
bp	NULL
)	NULL
IgV	NULL
(	NULL
250	NULL
bp	NULL
)	NULL
B-globin	NULL
(	NULL
395	NULL
bp	NULL
)	NULL
CD38+CD77-	NULL
25/79	NULL
(	NULL
31.6	NULL
)	NULL
11/14	NULL
(	NULL
79	NULL
)	NULL
nd	NULL
40	NULL
(	NULL
0.04	NULL
)	NULL
¢	NULL
141	NULL
(	NULL
4.0	NULL
)	NULL
nd	NULL
CD38+CD77+	NULL
12/37	NULL
(	NULL
32.4	NULL
)	NULL
12/12	NULL
(	NULL
100	NULL
)	NULL
1/32	NULL
(	NULL
3	NULL
)	NULL
28	NULL
(	NULL
0.07	NULL
)	NULL
$	NULL
184	NULL
(	NULL
6.1	NULL
)	NULL
1	NULL
(	NULL
0.004	NULL
)	NULL
IgD+CD27-	NULL
2/35	NULL
(	NULL
5.7	NULL
)	NULL
2/16	NULL
(	NULL
12.5	NULL
)	NULL
nd	NULL
3	NULL
(	NULL
0.009	NULL
)	NULL
%	NULL
§	NULL
8	NULL
(	NULL
0.2	NULL
)	NULL
nd	NULL
*Number	NULL
of	NULL
cells	NULL
harboring	NULL
mutations	NULL
over	NULL
total	NULL
number	NULL
of	NULL
cells	NULL
sequenced	NULL
.	NULL

On	NULL
average	NULL
,	NULL
>	NULL
90	NULL
%	NULL
of	NULL
the	NULL
samples	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
positive	NULL
PCR	NULL
product	NULL
when	NULL
the	NULL
BCL-6	NULL
and	NULL
-globin	NULL
gene	NULL
were	NULL
amplified	NULL
;	NULL
the	NULL
amplification	NULL
rate	NULL
for	NULL
the	NULL
Ig	NULL
V	NULL
genes	NULL
ranged	NULL
from	NULL
20	NULL
to	NULL
70	NULL
%	NULL
in	NULL
different	NULL
experiments	NULL
{	NULL
average	NULL
:	NULL
50	NULL
%	NULL
in	NULL
centrocytes	NULL
and	NULL
naive	NULL
B	NULL
cells	NULL
,	NULL
36	NULL
%	NULL
in	NULL
centroblasts	NULL
)	NULL
.	NULL

Total	NULL
number	NULL
of	NULL
mutations	NULL
found	NULL
.	NULL

Percentages	NULL
were	NULL
calculated	NULL
by	NULL
dividing	NULL
the	NULL
number	NULL
of	NULL
mutational	NULL
events	NULL
by	NULL
the	NULL
total	NULL
number	NULL
of	NULL
base	NULL
pairs	NULL
analyzed	NULL
(	NULL
1,484	NULL
bp	NULL
when	NULL
both	NULL
BCL-6	NULL
alleles	NULL
were	NULL
amplified	NULL
)	NULL
.	NULL

For	NULL
the	NULL
BCL-6	NULL
gene	NULL
:	NULL
centrocytes	NULL
=	NULL
88,298	NULL
bp	NULL
,	NULL
centroblasts	NULL
=	NULL
39,326	NULL
bp	NULL
,	NULL
and	NULL
naive	NULL
B	NULL
cells	NULL
=	NULL
31,164	NULL
bp	NULL
.	NULL

Values	NULL
displaying	NULL
statistically	NULL
significant	NULL
differences	NULL
are	NULL
marked	NULL
by	NULL
identical	NULL
symbols	NULL
:	NULL
£P	NULL
=	NULL
0.017	NULL
;	NULL
§P	NULL
=	NULL
0.010.	NULL
nd	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

Immunology	NULL
:	NULL
Pasqualuceci	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
(	NULL
1998	NULL
)	NULL
-	NULL
11819	NULL
Table	NULL
2	NULL
.	NULL

Distribution	NULL
of	NULL
BCL-6	NULL
mutations	NULL
in	NULL
neoplastic	NULL
diseases	NULL
Histology	NULL
Mutated/tested	NULL
%	NULL
Normal	NULL
counterpart	NULL
B	NULL
cell	NULL
malignancies	NULL
B-ALL	NULL
0/19	NULL
0	NULL
Pre-B	NULL
cell	NULL
MCL	NULL
1/19	NULL
5	NULL
Pre-GC	NULL
B	NULL
cell	NULL
B-CLL	NULL
5/33	NULL
15	NULL
CD5+	NULL
B	NULL
cell	NULL
FL	NULL
10/27	NULL
37	NULL
GC	NULL
B	NULL
cell	NULL
BL*	NULL
11/30	NULL
37	NULL
GC	NULL
B	NULL
cell	NULL
DLCL	NULL
48/81	NULL
59	NULL
GC	NULL
B	NULL
cell	NULL
MM	NULL
19/58	NULL
33	NULL
Post-GC	NULL
B	NULL
cell	NULL
Non-B	NULL
cell	NULL
malignancies	NULL
T	NULL
cell	NULL
neoplasmst	NULL
2/35	NULL
6	NULL
T	NULL
cell	NULL
Myeloid	NULL
leukemiast	NULL
0/52	NULL
0	NULL
Stem	NULL
cell/myeloid	NULL
cell	NULL
Solid	NULL
tumors§	NULL
0/123	NULL
0	NULL
Various	NULL
*Including	NULL
17	NULL
cases	NULL
and	NULL
13	NULL
cell	NULL
lines	NULL
.	NULL

*T	NULL
cell	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
(	NULL
six	NULL
cases	NULL
)	NULL
,	NULL
T-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
(	NULL
14	NULL
cases	NULL
)	NULL
,	NULL
peripheral	NULL
T	NULL
cell	NULL
lymphoma	NULL
(	NULL
15	NULL
cases	NULL
)	NULL
.	NULL

fAcute	NULL
myeloid	NULL
leukemia	NULL
(	NULL
44	NULL
cases	NULL
)	NULL
and	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
(	NULL
eight	NULL
cases	NULL
)	NULL
.	NULL

$	NULL
Breast	NULL
,	NULL
prostate	NULL
,	NULL
stomach	NULL
,	NULL
colon	NULL
,	NULL
liver	NULL
,	NULL
and	NULL
kidney	NULL
carcinomas	NULL
and	NULL
glioblastomas	NULL
(	NULL
data	NULL
from	NULL
ref	NULL
.	NULL

9	NULL
)	NULL
.	NULL

B-ALL	NULL
,	NULL
B-cell	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
;	NULL
MCL	NULL
,	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
;	NULL
B-CLL	NULL
,	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
;	NULL
MM	NULL
,	NULL
multiple	NULL
myeloma	NULL
.	NULL

which	NULL
the	NULL
occurrence	NULL
of	NULL
BCL-6	NULL
substitutions	NULL
was	NULL
restricted	NULL
to	NULL
the	NULL
subset	NULL
carrying	NULL
Ig	NULL
V	NULL
;	NULL
mutations	NULL
(	NULL
28	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
BCL-6	NULL
mutations	NULL
are	NULL
introduced	NULL
in	NULL
the	NULL
same	NULL
tumor	NULL
types	NULL
as	NULL
IgV	NULL
mutations	NULL
,	NULL
suggesting	NULL
their	NULL
derivation	NULL
from	NULL
a	NULL
common	NULL
mechanism	NULL
.	NULL

Features	NULL
of	NULL
BCL-6	NULL
and	NULL
IgVy	NULL
Mutations	NULL
in	NULL
Normal	NULL
and	NULL
Transformed	NULL
Cells	NULL
.	NULL

The	NULL
comparative	NULL
analysis	NULL
of	NULL
636	NULL
independent	NULL
substitutions	NULL
from	NULL
the	NULL
BCL-6	NULL
5'-noncoding	NULL
region	NULL
(	NULL
r	NULL
=	NULL
124	NULL
)	NULL
and	NULL
the	NULL
Ig	NULL
Vy	NULL
genes	NULL
(	NULL
n	NULL
=	NULL
512	NULL
)	NULL
in	NULL
normal	NULL
GC	NULL
cells	NULL
and	NULL
DLCL	NULL
is	NULL
summarized	NULL
in	NULL
Table	NULL
3	NULL
.	NULL

For	NULL
both	NULL
BCL-6	NULL
and	NULL
Ig	NULL
Vx	NULL
mutations	NULL
,	NULL
the	NULL
frequency	NULL
was	NULL
higher	NULL
in	NULL
tumor	NULL
than	NULL
in	NULL
normal	NULL
GC	NULL
cells	NULL
.	NULL

For	NULL
both	NULL
loci	NULL
,	NULL
mutations	NULL
almost	NULL
were	NULL
exclusively	NULL
represented	NULL
by	NULL
single	NULL
base	NULL
pair	NULL
substitutions	NULL
,	NULL
and	NULL
transitions	NULL
were	NULL
more	NULL
common	NULL
than	NULL
transversions	NULL
(	NULL
BCL-6	NULL
:	NULL
55	NULL
%	NULL
vs.	NULL
45	NULL
%	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
and	NULL
54.5	NULL
%	NULL
vs.	NULL
45.5	NULL
%	NULL
in	NULL
DLCL	NULL
,	NULL
despite	NULL
the	NULL
potential	NULL
for	NULL
twice	NULL
as	NULL
many	NULL
transversion	NULL
events	NULL
)	NULL
.	NULL

In	NULL
the	NULL
two	NULL
categories	NULL
analyzed	NULL
,	NULL
small	NULL
deletions	NULL
represented	NULL
3	NULL
%	NULL
and	NULL
5.3	NULL
%	NULL
of	NULL
the	NULL
mutations	NULL
,	NULL
respectively	NULL
.	NULL

However	NULL
,	NULL
no	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
frequency	NULL
of	NULL
mutations	NULL
affecting	NULL
each	NULL
base	NULL
were	NULL
found	NULL
after	NULL
correction	NULL
for	NULL
the	NULL
base	NULL
composition	NULL
of	NULL
the	NULL
BCL-6	NULL
region	NULL
(	NULL
in	NULL
normal	NULL
GC	NULL
cells	NULL
,	NULL
C	NULL
=	NULL
33	NULL
%	NULL
,	NULL
G	NULL
=	NULL
24	NULL
%	NULL
,	NULL
T	NULL
=	NULL
22	NULL
%	NULL
,	NULL
and	NULL
A	NULL
=	NULL
21	NULL
%	NULL
;	NULL
in	NULL
DLCL	NULL
,	NULL
C	NULL
,	NULL
G	NULL
,	NULL
T	NULL
,	NULL
and	NULL
A	NULL
substitutions	NULL
accounted	NULL
p	NULL
25	NULL
1.6	NULL
-	NULL
o	NULL
BCL-6	NULL
o	NULL
pa	NULL
PS	NULL
*	NULL
IgVH	NULL
a	NULL
.	NULL

``	NULL
I	NULL
a	NULL
a	NULL
0	NULL
a	NULL
a	NULL
¢	NULL
2	NULL
0	NULL
1.07	NULL
*	NULL
*	NULL
>	NULL
X	NULL
F	NULL
o	NULL
x	NULL
o	NULL
3	NULL
&	NULL
5	NULL
©	NULL
0	NULL
0.8	NULL
4	NULL
&	NULL
-3	NULL
*	NULL
*	NULL
150	NULL
£	NULL
R	NULL
>	NULL
s	NULL
O	NULL
©	NULL
€	NULL
=	NULL
[	NULL
=	NULL
0.6	NULL
-	NULL
0	NULL
be	NULL
e	NULL
£	NULL
®	NULL
e	NULL
o	NULL
e	NULL
a	NULL
C	NULL
E	NULL
j	NULL
``	NULL
o	NULL
o	NULL
fio	NULL
$	NULL
S	NULL
e	NULL
*	NULL
®	NULL
S	NULL
$	NULL
3	NULL
e	NULL
3	NULL
S	NULL
-	NULL
0.4	NULL
-	NULL
o	NULL
S	NULL
g.	NULL
*	NULL
¥	NULL
0	NULL
=e	NULL
g	NULL
0	NULL
*	NULL
O	NULL
e	NULL
&	NULL
0	NULL
0	NULL
c	NULL
C	NULL
p58	NULL
_	NULL
g	NULL
-I	NULL
0	NULL
3	NULL
0.2	NULL
0	NULL
0	NULL
5	NULL
LL	NULL
ve	NULL
co	NULL
LE	NULL
&	NULL
0	NULL
O	NULL
©000	NULL
C0	NULL
©000	NULL
©000	NULL
000	NULL
@	NULL
Q	NULL
|	NULL
-	NULL
f	NULL
0	NULL
MCL	NULL
CLL	NULL
FL	NULL
BL	NULL
DLCL	NULL
MM	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Comparative	NULL
analysis	NULL
of	NULL
the	NULL
mutation	NULL
frequency	NULL
in	NULL
the	NULL
BCL-6	NULL
5'-noncoding	NULL
region	NULL
and	NULL
Ig	NULL
V	NULL
;	NULL
;	NULL
segments	NULL
of	NULL
B	NULL
cell	NULL
lymphoid	NULL
malignancies	NULL
.	NULL

Five	NULL
cases	NULL
representative	NULL
of	NULL
the	NULL
major	NULL
histologic	NULL
subtypes	NULL
and	NULL
showing	NULL
BCL-6	NULL
alterations	NULL
upon	NULL
SSCP	NULL
analysis	NULL
were	NULL
randomly	NULL
selected	NULL
,	NULL
along	NULL
with	NULL
five	NULL
mantle	NULL
cell	NULL
lymphomas	NULL
.	NULL

A	NULL
742-bp	NULL
region	NULL
of	NULL
the	NULL
BCL-6	NULL
first	NULL
intron	NULL
and	NULL
the	NULL
rearranged	NULL
Ig	NULL
V	NULL
;	NULL
;	NULL
genes	NULL
from	NULL
the	NULL
same	NULL
patients	NULL
were	NULL
amplified	NULL
and	NULL
directly	NULL
sequenced	NULL
.	NULL

Filled	NULL
and	NULL
empty	NULL
circles	NULL
represent	NULL
the	NULL
frequency	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
two	NULL
loci	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
cases	NULL
in	NULL
each	NULL
category	NULL
harbored	NULL
one	NULL
to	NULL
two	NULL
nucleotide	NULL
substitutions	NULL
(	NULL
0.068-0.13	NULL
%	NULL
)	NULL
;	NULL
particularly	NULL
high	NULL
values	NULL
were	NULL
found	NULL
in	NULL
one	NULL
FL	NULL
(	NULL
n	NULL
=	NULL
9	NULL
,	NULL
0.6	NULL
%	NULL
)	NULL
,	NULL
one	NULL
BL	NULL
(	NULL
r	NULL
=	NULL
16	NULL
,	NULL
1.1	NULL
%	NULL
)	NULL
,	NULL
and	NULL
various	NULL
DLCL	NULL
cases	NULL
(	NULL
n	NULL
=	NULL
5-24	NULL
,	NULL
0.34-1.6	NULL
%	NULL
)	NULL
.	NULL

11820	NULL
_	NULL
Immunology	NULL
:	NULL
Pasqualuceci	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
(	NULL
1998	NULL
)	NULL
Table	NULL
3	NULL
.	NULL

Features	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
BCL-6	NULL
5'-noncoding	NULL
region	NULL
and	NULL
Ig	NULL
Vy	NULL
genes	NULL
of	NULL
normal	NULL
GC	NULL
cells	NULL
vs.	NULL
DLCL	NULL
BCL-6	NULL
Normal	NULL
GC	NULL
DLCL	NULL
Normal	NULL
GC	NULL
DLCL	NULL
Frequency	NULL
x	NULL
10~*/bp	NULL
(	NULL
range	NULL
)	NULL
0.05	NULL
(	NULL
0-0.4	NULL
)	NULL
0.23	NULL
(	NULL
0-1.6	NULL
)	NULL
*	NULL
5	NULL
(	NULL
0-13	NULL
)	NULL
15.2	NULL
(	NULL
6.3-20.5	NULL
)	NULL
Single	NULL
bp	NULL
substitutions	NULL
66	NULL
53	NULL
323	NULL
187	NULL
Deletions	NULL
2	NULL
3	NULL
2	NULL
0	NULL
Transitions/transversionst	NULL
1.2	NULL
1.2	NULL
1.4	NULL
1.2	NULL
Strand	NULL
polarity'*	NULL
1	NULL
1.1	NULL
1.9	NULL
1.5	NULL
RGYW	NULL
bias§	NULL
0.21	NULL
(	NULL
<	NULL
0.05	NULL
)	NULL
1.2	NULL
(	NULL
<	NULL
0.05	NULL
)	NULL
21.3	NULL
(	NULL
<	NULL
0.001	NULL
)	NULL
53	NULL
(	NULL
<	NULL
0.001	NULL
)	NULL
*The	NULL
overall	NULL
frequency	NULL
of	NULL
BCL-6	NULL
mutations	NULL
in	NULL
DLCL	NULL
is	NULL
extrapolated	NULL
from	NULL
the	NULL
frequency	NULL
of	NULL
mutated	NULL
cases	NULL
occurring	NULL
in	NULL
this	NULL
group	NULL
(	NULL
60	NULL
%	NULL
)	NULL
.	NULL

*The	NULL
frequency	NULL
of	NULL
substitutions	NULL
affecting	NULL
each	NULL
base	NULL
was	NULL
corrected	NULL
for	NULL
the	NULL
base	NULL
composition	NULL
of	NULL
the	NULL
region	NULL
analyzed	NULL
.	NULL

£Values	NULL
designate	NULL
the	NULL
ratio	NULL
of	NULL
A	NULL
-	NULL
>	NULL
N	NULL
vs.	NULL
T	NULL
-	NULL
>	NULL
N	NULL
substitutions	NULL
.	NULL

$	NULL
Normalized	NULL
frequency	NULL
of	NULL
mutated	NULL
G	NULL
bases	NULL
occurring	NULL
in	NULL
the	NULL
context	NULL
of	NULL
an	NULL
RGYW	NULL
motif	NULL
(	NULL
see	NULL
text	NULL
)	NULL
.	NULL

In	NULL
parenthesis	NULL
,	NULL
the	NULL
statistical	NULL
significance	NULL
compared	NULL
with	NULL
the	NULL
expected	NULL
frequency	NULL
of	NULL
mutations	NULL
is	NULL
shown	NULL
,	NULL
as	NULL
calculated	NULL
by	NULL
the	NULL
y	NULL
``	NULL
test	NULL
.	NULL

for	NULL
25	NULL
%	NULL
,	NULL
27	NULL
%	NULL
,	NULL
23	NULL
%	NULL
,	NULL
and	NULL
25	NULL
%	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
mutation	NULL
pattern	NULL
of	NULL
BCL-6	NULL
does	NULL
not	NULL
indicate	NULL
a	NULL
preferential	NULL
bias	NULL
of	NULL
A	NULL
:	NULL
N	NULL
over	NULL
T	NULL
:	NULL
N	NULL
templates	NULL
,	NULL
suggesting	NULL
the	NULL
absence	NULL
of	NULL
strand	NULL
polarity	NULL
,	NULL
a	NULL
feature	NULL
reported	NULL
for	NULL
IgV	NULL
mutations	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
(	NULL
31	NULL
)	NULL
.	NULL

A	NULL
variety	NULL
of	NULL
studies	NULL
have	NULL
recognized	NULL
specific	NULL
nucleotide	NULL
motifs	NULL
within	NULL
the	NULL
Ig	NULL
genes	NULL
as	NULL
intrinsic	NULL
hotspots	NULL
for	NULL
somatic	NULL
hypermutation	NULL
:	NULL
among	NULL
them	NULL
,	NULL
the	NULL
consensus	NULL
RGYW	NULL
(	NULL
where	NULL
R	NULL
=	NULL
purine	NULL
,	NULL
Y	NULL
=	NULL
pyrimidine	NULL
,	NULL
and	NULL
W	NULL
=	NULL
A	NULL
or	NULL
T	NULL
)	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
most	NULL
frequently	NULL
mutated	NULL
one	NULL
(	NULL
31-33	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
there	NULL
is	NULL
preferential	NULL
targeting	NULL
of	NULL
the	NULL
RGYW	NULL
motif	NULL
in	NULL
the	NULL
BCL-6	NULL
locus	NULL
,	NULL
the	NULL
number	NULL
of	NULL
G	NULL
mutations	NULL
within	NULL
the	NULL
RGYW	NULL
motif	NULL
was	NULL
normalized	NULL
for	NULL
its	NULL
frequency	NULL
in	NULL
the	NULL
region	NULL
investigated	NULL
and	NULL
compared	NULL
with	NULL
the	NULL
expected	NULL
frequency	NULL
of	NULL
mutations	NULL
in	NULL
both	NULL
normal	NULL
GC	NULL
B	NULL
cells	NULL
and	NULL
DLCLs	NULL
.	NULL

For	NULL
BCL-6	NULL
,	NULL
the	NULL
actual	NULL
occurrence	NULL
of	NULL
bp	NULL
changes	NULL
within	NULL
the	NULL
RGYW	NULL
motif	NULL
was	NULL
found	NULL
to	NULL
differ	NULL
from	NULL
that	NULL
expected	NULL
by	NULL
chance	NULL
alone	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
preferential	NULL
targeting	NULL
.	NULL

This	NULL
bias	NULL
,	NULL
however	NULL
,	NULL
was	NULL
less	NULL
evident	NULL
than	NULL
in	NULL
the	NULL
IgV	NULL
»	NULL
sequences	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
observations	NULL
indicate	NULL
that	NULL
the	NULL
features	NULL
of	NULL
BCL-6	NULL
and	NULL
IgV	NULL
mutations	NULL
are	NULL
similar	NULL
,	NULL
consistent	NULL
with	NULL
both	NULL
sets	NULL
of	NULL
mutations	NULL
being	NULL
produced	NULL
by	NULL
the	NULL
same	NULL
mechanism	NULL
.	NULL

DISCUSSION	NULL
This	NULL
study	NULL
reports	NULL
that	NULL
the	NULL
5'-noncoding	NULL
region	NULL
of	NULL
the	NULL
BCL-6	NULL
gene	NULL
is	NULL
targeted	NULL
by	NULL
a	NULL
somatic	NULL
hypermutation	NULL
mechanism	NULL
operating	NULL
in	NULL
normal	NULL
GC	NULL
B	NULL
cells	NULL
.	NULL

An	NULL
analysis	NULL
of	NULL
transformed	NULL
counterparts	NULL
of	NULL
B	NULL
cells	NULL
at	NULL
various	NULL
differentiation	NULL
stages	NULL
confirms	NULL
a	NULL
close	NULL
association	NULL
among	NULL
BCL-6	NULL
mutations	NULL
,	NULL
IgV	NULL
mutations	NULL
,	NULL
and	NULL
GC	NULL
transit	NULL
.	NULL

These	NULL
findings	NULL
provide	NULL
evidence	NULL
that	NULL
somatic	NULL
hypermutation	NULL
is	NULL
not	NULL
limited	NULL
to	NULL
the	NULL
Ig	NULL
locus	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
with	NULL
implications	NULL
for	NULL
the	NULL
mechanism	NULL
of	NULL
hypermutation	NULL
as	NULL
well	NULL
as	NULL
its	NULL
role	NULL
in	NULL
B	NULL
cell	NULL
function	NULL
and	NULL
lymphomagenesis	NULL
.	NULL

Relationship	NULL
Between	NULL
BCL-6	NULL
and	NULL
IgV	NULL
Mutations	NULL
.	NULL

Several	NULL
observations	NULL
suggest	NULL
that	NULL
BCL-6	NULL
mutations	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
same	NULL
mechanism	NULL
generating	NULL
IgV	NULL
mutations	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

First	NULL
,	NULL
our	NULL
results	NULL
show	NULL
that	NULL
in	NULL
both	NULL
normal	NULL
and	NULL
malignant	NULL
cells	NULL
BCL-6	NULL
mutations	NULL
selectively	NULL
occur	NULL
in	NULL
GCs	NULL
,	NULL
the	NULL
physiologic	NULL
site	NULL
of	NULL
IgV	NULL
hypermutation	NULL
(	NULL
1-4	NULL
)	NULL
.	NULL

The	NULL
detection	NULL
of	NULL
BCL-6	NULL
mutations	NULL
in	NULL
a	NULL
subset	NULL
of	NULL
CLL	NULL
cases	NULL
also	NULL
is	NULL
consistent	NULL
with	NULL
this	NULL
notion	NULL
because	NULL
the	NULL
same	NULL
cases	NULL
displayed	NULL
nucleotide	NULL
exchanges	NULL
in	NULL
their	NULL
Ig	NULL
Vx	NULL
loci	NULL
,	NULL
indicating	NULL
a	NULL
GC	NULL
transit	NULL
of	NULL
the	NULL
putative	NULL
precursor	NULL
cell	NULL
.	NULL

Second	NULL
,	NULL
BCL-6	NULL
mutations	NULL
share	NULL
most	NULL
of	NULL
the	NULL
features	NULL
of	NULL
IgV	NULL
mutations	NULL
,	NULL
including	NULL
the	NULL
preference	NULL
for	NULL
single	NULL
base	NULL
pair	NULL
substitutions	NULL
with	NULL
a	NULL
small	NULL
number	NULL
of	NULL
deletions	NULL
,	NULL
the	NULL
predominance	NULL
of	NULL
transitions	NULL
over	NULL
transversions	NULL
,	NULL
and	NULL
some	NULL
degree	NULL
of	NULL
preferential	NULL
motif	NULL
(	NULL
RGYW	NULL
)	NULL
targeting	NULL
(	NULL
22	NULL
,	NULL
31-35	NULL
)	NULL
.	NULL

Third	NULL
,	NULL
both	NULL
BCL-6	NULL
and	NULL
IgV	NULL
mutations	NULL
are	NULL
associated	NULL
with	NULL
transcribed	NULL
sequences	NULL
.	NULL

Intriguingly	NULL
,	NULL
BCL-6	NULL
mutations	NULL
,	NULL
as	NULL
IgV	NULL
mutations	NULL
,	NULL
are	NULL
scattered	NULL
within	NULL
2	NULL
kb	NULL
from	NULL
the	NULL
transcriptional	NULL
initiation	NULL
site	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
BCL-6	NULL
mutations	NULL
appears	NULL
to	NULL
be	NULL
significantly	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
IgVy	NULL
mutations	NULL
in	NULL
both	NULL
normal	NULL
and	NULL
neoplastic	NULL
cells	NULL
.	NULL

The	NULL
basis	NULL
for	NULL
this	NULL
difference	NULL
is	NULL
not	NULL
known	NULL
,	NULL
but	NULL
it	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
correlate	NULL
with	NULL
a	NULL
lower	NULL
transcription	NULL
rate	NULL
,	NULL
because	NULL
the	NULL
BCL-6	NULL
gene	NULL
is	NULL
transcribed	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
GC	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

While	NULL
this	NULL
manuscript	NULL
was	NULL
in	NULL
preparation	NULL
,	NULL
another	NULL
study	NULL
has	NULL
reported	NULL
the	NULL
occurrence	NULL
of	NULL
BCL-6	NULL
mutations	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
.	NULL

The	NULL
frequency	NULL
,	NULL
type	NULL
,	NULL
and	NULL
distribution	NULL
of	NULL
nucleotide	NULL
substitutions	NULL
are	NULL
similar	NULL
in	NULL
the	NULL
two	NULL
studies	NULL
,	NULL
although	NULL
a	NULL
strand	NULL
bias	NULL
was	NULL
noted	NULL
by	NULL
Shen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
37	NULL
)	NULL
that	NULL
was	NULL
not	NULL
detectable	NULL
in	NULL
our	NULL
analysis	NULL
.	NULL

Overall	NULL
,	NULL
these	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
BCL-6	NULL
and	NULL
IgV	NULL
mutations	NULL
represent	NULL
the	NULL
product	NULL
of	NULL
the	NULL
same	NULL
mechanism	NULL
.	NULL

Implications	NULL
for	NULL
the	NULL
Somatic	NULL
Hypermutation	NULL
Mechanism	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
a	NULL
new	NULL
locus	NULL
undergoing	NULL
somatic	NULL
hypermutation	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
prompted	NULL
a	NULL
reexamination	NULL
of	NULL
some	NULL
of	NULL
the	NULL
known	NULL
functional	NULL
requirements	NULL
for	NULL
the	NULL
IgV	NULL
hypermutation	NULL
mechanism	NULL
.	NULL

The	NULL
BCL-6	NULL
5'-noncoding	NULL
region	NULL
and	NULL
the	NULL
IgV	NULL
sequences	NULL
do	NULL
not	NULL
share	NULL
primary	NULL
sequence	NULL
homologies	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
somatic	NULL
hypermutation	NULL
is	NULL
a	NULL
target	NULL
sequence-independent	NULL
process	NULL
and	NULL
does	NULL
not	NULL
require	NULL
a	NULL
specific	NULL
promoter	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

The	NULL
occurrence	NULL
of	NULL
BCL-6	NULL
mutations	NULL
downstream	NULL
of	NULL
the	NULL
promoter	NULL
region	NULL
is	NULL
comparable	NULL
with	NULL
that	NULL
observed	NULL
in	NULL
rearranged	NULL
IgV	NULL
genes	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
hypermutation	NULL
process	NULL
may	NULL
be	NULL
targeted	NULL
to	NULL
a	NULL
specific	NULL
distance	NULL
from	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
(	NULL
7	NULL
,	NULL
33	NULL
)	NULL
.	NULL

As	NULL
IgV	NULL
hypermutation	NULL
requires	NULL
the	NULL
Ig	NULL
enhancer	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
the	NULL
BCL-6	NULL
locus	NULL
also	NULL
contains	NULL
a	NULL
cis-acting	NULL
transcriptional	NULL
control	NULL
element	NULL
structurally	NULL
or	NULL
functionally	NULL
similar	NULL
to	NULL
the	NULL
Ig	NULL
enhancer	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
such	NULL
an	NULL
element	NULL
should	NULL
provide	NULL
insight	NULL
into	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
hypermutation	NULL
is	NULL
targeted	NULL
to	NULL
specific	NULL
loci	NULL
.	NULL

Role	NULL
of	NULL
BCL-6	NULL
Mutations	NULL
in	NULL
Normal	NULL
and	NULL
Transformed	NULL
B	NULL
Cells	NULL
.	NULL

The	NULL
functional	NULL
significance	NULL
of	NULL
mutations	NULL
introduced	NULL
into	NULL
the	NULL
BCL-6	NULL
5'-regulatory	NULL
region	NULL
of	NULL
normal	NULL
B	NULL
cells	NULL
is	NULL
unknown	NULL
.	NULL

Because	NULL
these	NULL
mutations	NULL
have	NULL
been	NULL
found	NULL
at	NULL
a	NULL
comparable	NULL
frequency	NULL
in	NULL
normal	NULL
memory	NULL
B	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
as	NULL
well	NULL
as	NULL
in	NULL
multiple	NULL
myeloma	NULL
,	NULL
which	NULL
represents	NULL
transformed	NULL
plasma	NULL
cells	NULL
,	NULL
our	NULL
study	NULL
indicates	NULL
that	NULL
cells	NULL
carrying	NULL
BCL-6	NULL
mutations	NULL
are	NULL
neither	NULL
significantly	NULL
counterselected	NULL
nor	NULL
positively	NULL
selected	NULL
in	NULL
the	NULL
GC	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
mutations	NULL
is	NULL
not	NULL
clearly	NULL
different	NULL
in	NULL
normal	NULL
and	NULL
malignant	NULL
B	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
most	NULL
of	NULL
the	NULL
mutations	NULL
found	NULL
in	NULL
tumors	NULL
may	NULL
not	NULL
have	NULL
any	NULL
pathologic	NULL
effect	NULL
.	NULL

However	NULL
,	NULL
initial	NULL
studies	NULL
on	NULL
several	NULL
tumor-derived	NULL
BCL-6	NULL
alleles	NULL
indicate	NULL
that	NULL
few	NULL
mutations	NULL
can	NULL
significantly	NULL
deregulate	NULL
BCL-6	NULL
expression	NULL
,	NULL
whereas	NULL
others	NULL
are	NULL
apparently	NULL
functionally	NULL
irrelevant	NULL
or	NULL
associated	NULL
with	NULL
silent	NULL
alleles	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

The	NULL
~740-bp	NULL
intronic	NULL
sequence	NULL
corresponding	NULL
to	NULL
the	NULL
major	NULL
cluster	NULL
of	NULL
BCL-6	NULL
mutations	NULL
contains	NULL
several	NULL
regions	NULL
of	NULL
high	NULL
evolutionary	NULL
conservation	NULL
,	NULL
suggesting	NULL
that	NULL
some	NULL
mutations	NULL
may	NULL
hit	NULL
regulatory	NULL
domains	NULL
of	NULL
the	NULL
BCL-6	NULL
gene	NULL
and	NULL
influence	NULL
its	NULL
mode	NULL
of	NULL
expression	NULL
.	NULL

A	NULL
functional	NULL
dissection	NULL
of	NULL
the	NULL
BCL-6	NULL
5'-noncoding	NULL
region	NULL
is	NULL
needed	NULL
to	NULL
address	NULL
these	NULL
issues	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
identification	NULL
of	NULL
BCL-6	NULL
mutations	NULL
suggests	NULL
the	NULL
possibility	NULL
that	NULL
other	NULL
sequences	NULL
may	NULL
be	NULL
subjected	NULL
to	NULL
the	NULL
hypermutation	NULL
process	NULL
in	NULL
GCs	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
role	NULL
of	NULL
somatic	NULL
hypermutation	NULL
is	NULL
not	NULL
limited	NULL
to	NULL
generate	NULL
antibody	NULL
diversity	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Structural	NULL
and	NULL
functional	NULL
similarities	NULL
Immunology	NULL
:	NULL
Pasqualuceci	NULL
et	NULL
al	NULL
.	NULL

between	NULL
BCL-6	NULL
and	NULL
Ig	NULL
loci	NULL
may	NULL
be	NULL
useful	NULL
to	NULL
identify	NULL
other	NULL
possible	NULL
targets	NULL
of	NULL
the	NULL
hypermutation	NULL
process	NULL
.	NULL

We	NULL
thank	NULL
Ulla	NULL
Beauchamp	NULL
for	NULL
expert	NULL
assistance	NULL
with	NULL
DNA	NULL
sequencing	NULL
and	NULL
Alexander	NULL
Scheffold	NULL
for	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
the	NULL
anti-Digoxigenin	NULL
liposomes	NULL
.	NULL

This	NULL
study	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
CA-44029	NULL
and	NULL
CA-75553	NULL
and	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Associazione	NULL
Italiana	NULL
per	NULL
la	NULL
Ricerca	NULL
sul	NULL
Cancro	NULL
(	NULL
to	NULL
A.N	NULL
.	NULL
)	NULL

.	NULL

L.P.	NULL
is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
Fellowship	NULL
from	NULL
the	NULL
Associazione	NULL
Italiana	NULL
per	NULL
la	NULL
Ricerca	NULL
sul	NULL
Cancro	NULL
.	NULL

1	NULL
.	NULL

2	NULL
.	NULL

3	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

Rajewsky	NULL
,	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
381	NULL
,	NULL
751-758	NULL
.	NULL

Jacob	NULL
,	NULL
J.	NULL
,	NULL
Kelsoe	NULL
,	NULL
G.	NULL
,	NULL
Rajewsky	NULL
,	NULL
K.	NULL
&	NULL
Weiss	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
354	NULL
,	NULL
389-392	NULL
.	NULL

Berek	NULL
,	NULL
C.	NULL
,	NULL
Berger	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Apel	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
67	NULL
,	NULL
1121-1129	NULL
.	NULL

Kiippers	NULL
,	NULL
R.	NULL
,	NULL
Zhao	NULL
,	NULL
M.	NULL
,	NULL
Hansmann	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Rajewsky	NULL
,	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
4955-4967	NULL
.	NULL

Klein	NULL
,	NULL
U.	NULL
,	NULL
Goossens	NULL
,	NULL
T.	NULL
,	NULL
Fischer	NULL
,	NULL
M.	NULL
,	NULL
Kanzler	NULL
,	NULL
H.	NULL
,	NULL
Bracuninger	NULL
,	NULL
A.	NULL
,	NULL
Rajewsky	NULL
,	NULL
K.	NULL
&	NULL
Kiippers	NULL
,	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

162	NULL
,	NULL
261-280	NULL
.	NULL

Betz	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Milstein	NULL
,	NULL
C.	NULL
,	NULL
Gonzalez-Fernandez	NULL
,	NULL
A.	NULL
,	NULL
Pannell	NULL
,	NULL
R.	NULL
,	NULL
Larson	NULL
,	NULL
T.	NULL
&	NULL
Neuberger	NULL
,	NULL
M.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
77	NULL
,	NULL
239-248	NULL
.	NULL

Peters	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Storb	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Immunity	NULL
4	NULL
,	NULL
57-65	NULL
.	NULL

Yelamos	NULL
,	NULL
J.	NULL
,	NULL
Klix	NULL
,	NULL
N.	NULL
,	NULL
Goyenechea	NULL
,	NULL
B.	NULL
,	NULL
Lozano	NULL
,	NULL
F.	NULL
,	NULL
Chui	NULL
,	NULL
Y.	NULL
L.	NULL
,	NULL
Gonzalez	NULL
Fernandez	NULL
,	NULL
A.	NULL
,	NULL
Pannell	NULL
,	NULL
R.	NULL
,	NULL
Neuberger	NULL
,	NULL
M.	NULL
S.	NULL
&	NULL
Milstein	NULL
,	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
376	NULL
,	NULL
225-229	NULL
.	NULL

Migliazza	NULL
,	NULL
A.	NULL
,	NULL
Martinotti	NULL
,	NULL
S.	NULL
,	NULL
Chen	NULL
,	NULL
W.	NULL
,	NULL
Fusco	NULL
,	NULL
C.	NULL
,	NULL
Ye	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Knowles	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Offit	NULL
,	NULL
K.	NULL
,	NULL
Chaganti	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
&	NULL
Dalla-Favera	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
,	NULL
12520-12524	NULL
.	NULL

Gaidano	NULL
,	NULL
G.	NULL
,	NULL
Carbone	NULL
,	NULL
A.	NULL
,	NULL
Pastore	NULL
,	NULL
C.	NULL
,	NULL
Capello	NULL
,	NULL
D.	NULL
,	NULL
Migliazza	NULL
,	NULL
A.	NULL
,	NULL
Gloghini	NULL
,	NULL
A.	NULL
,	NULL
Roncella	NULL
,	NULL
S.	NULL
,	NULL
Ferrarini	NULL
,	NULL
M.	NULL
,	NULL
Saglio	NULL
,	NULL
G.	NULL
&	NULL
Dalla-Favera	NULL
,	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
Blood	NULL
89	NULL
,	NULL
3755-3762	NULL
.	NULL

Ye	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Lista	NULL
,	NULL
F.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Knowles	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Offit	NULL
,	NULL
K.	NULL
,	NULL
Chaganti	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
&	NULL
Dalla-Favera	NULL
,	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
747-750	NULL
.	NULL

Kerckaert	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Deweindt	NULL
,	NULL
C.	NULL
,	NULL
Tilly	NULL
,	NULL
H.	NULL
,	NULL
Quief	NULL
,	NULL
S.	NULL
,	NULL
Lecocq	NULL
,	NULL
G.	NULL
&	NULL
Bastard	NULL
,	NULL
C.	NULL
(	NULL
1993	NULL
)	NULL
Nat	NULL
.	NULL

Genet	NULL
.	NULL

5	NULL
,	NULL
66-70	NULL
.	NULL

Chang	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Ye	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Chaganti	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
&	NULL
Dalla-Favera	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
,	NULL
6947-6952	NULL
.	NULL

Seyfert	NULL
,	NULL
V.	NULL
L.	NULL
,	NULL
Allman	NULL
,	NULL
D.	NULL
,	NULL
He	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Staudt	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Oncogene	NULL
12	NULL
,	NULL
2331-2342	NULL
.	NULL

Deweindt	NULL
,	NULL
C.	NULL
,	NULL
Albagli	NULL
,	NULL
O.	NULL
,	NULL
Bernardin	NULL
,	NULL
F.	NULL
,	NULL
Dhordain	NULL
,	NULL
P.	NULL
,	NULL
Quief	NULL
,	NULL
S.	NULL
,	NULL
Lantoine	NULL
,	NULL
D.	NULL
,	NULL
Kerckaert	NULL
,	NULL
J.	NULL
P.	NULL
&	NULL
Leprince	NULL
,	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

6	NULL
,	NULL
1495-1503	NULL
.	NULL

Cattoretti	NULL
,	NULL
G.	NULL
,	NULL
Chang	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Cechova	NULL
,	NULL
K.	NULL
,	NULL
Zhang	NULL
,	NULL
J.	NULL
,	NULL
Ye	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Falini	NULL
,	NULL
B.	NULL
,	NULL
Louie	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Offit	NULL
,	NULL
K.	NULL
,	NULL
Chaganti	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
&	NULL
Dalla-Favera	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
86	NULL
,	NULL
45-53	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
(	NULL
1998	NULL
)	NULL
-	NULL
11821	NULL
Onizuka	NULL
,	NULL
T.	NULL
,	NULL
Moriyama	NULL
,	NULL
M.	NULL
,	NULL
Yamochi	NULL
,	NULL
T.	NULL
,	NULL
Kuroda	NULL
,	NULL
T.	NULL
,	NULL
Kazama	NULL
,	NULL
A.	NULL
,	NULL
Kanazawa	NULL
,	NULL
N.	NULL
,	NULL
Sato	NULL
,	NULL
K.	NULL
,	NULL
Kato	NULL
,	NULL
T.	NULL
,	NULL
Ota	NULL
,	NULL
H.	NULL
&	NULL
Mori	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
86	NULL
,	NULL
28-37	NULL
.	NULL

Ye	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Cattoretti	NULL
,	NULL
G.	NULL
,	NULL
Shen	NULL
,	NULL
Q.	NULL
,	NULL
Zhang	NULL
,	NULL
J.	NULL
,	NULL
Hawe	NULL
,	NULL
N.	NULL
,	NULL
de	NULL
Waard	NULL
,	NULL
R.	NULL
,	NULL
Leung	NULL
,	NULL
C.	NULL
,	NULL
Nouri-Shirazi	NULL
,	NULL
M.	NULL
,	NULL
Orazi	NULL
,	NULL
A.	NULL
,	NULL
Chaganti	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Nat	NULL
.	NULL

Genet	NULL
.	NULL

16	NULL
,	NULL
161-170	NULL
.	NULL

Dent	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Shaffer	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Yu	NULL
,	NULL
X.	NULL
,	NULL
Allman	NULL
,	NULL
D.	NULL
&	NULL
Staudt	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Science	NULL
276	NULL
,	NULL
589-592	NULL
.	NULL

Fukuda	NULL
,	NULL
T.	NULL
,	NULL
Yoshida	NULL
,	NULL
T.	NULL
,	NULL
Okada	NULL
,	NULL
S.	NULL
,	NULL
Hatano	NULL
,	NULL
M.	NULL
,	NULL
Miki	NULL
,	NULL
T.	NULL
,	NULL
Ishibashi	NULL
,	NULL
K.	NULL
,	NULL
Okabe	NULL
,	NULL
S.	NULL
,	NULL
Koseki	NULL
,	NULL
H.	NULL
,	NULL
Hirosawa	NULL
,	NULL
S.	NULL
,	NULL
Taniguchi	NULL
,	NULL
M.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186	NULL
,	NULL
439-448	NULL
.	NULL

Kiippers	NULL
,	NULL
R.	NULL
,	NULL
Hansmann	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Rajewsky	NULL
,	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
in	NULL
Weir	NULL
's	NULL
Handbook	NULL
of	NULL
Experimental	NULL
Immunology	NULL
,	NULL
eds	NULL
.	NULL

Herzenberg	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Weir	NULL
,	NULL
D.	NULL
M.	NULL
&	NULL
Blackwell	NULL
,	NULL
D.	NULL
(	NULL
Blackwell	NULL
Scientific	NULL
,	NULL
Oxford	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

206.1-206.4	NULL
.	NULL

Goossens	NULL
,	NULL
T.	NULL
,	NULL
Klein	NULL
,	NULL
U	NULL
.	NULL

&	NULL
Kiippers	NULL
,	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
,	NULL
2463-2468	NULL
.	NULL

Klein	NULL
,	NULL
U.	NULL
,	NULL
Kiippers	NULL
,	NULL
R.	NULL
&	NULL
Rajewsky	NULL
,	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

23	NULL
,	NULL
3272-3277	NULL
.	NULL

Scheffold	NULL
,	NULL
A.	NULL
,	NULL
Miltenyi	NULL
,	NULL
S.	NULL
&	NULL
Radbruch	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunotech-nol	NULL
.	NULL

1	NULL
,	NULL
127-137	NULL
.	NULL

Kiippers	NULL
,	NULL
R.	NULL
,	NULL
Zhao	NULL
,	NULL
M.	NULL
,	NULL
Rajewsky	NULL
,	NULL
K.	NULL
&	NULL
Hansmann	NULL
,	NULL
M.	NULL
L.	NULL
(	NULL
1993	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

143	NULL
,	NULL
230-239	NULL
.	NULL

Klein	NULL
,	NULL
U.	NULL
,	NULL
Rajewsky	NULL
,	NULL
K.	NULL
&	NULL
Kiippers	NULL
,	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Weisenburger	NULL
,	NULL
D.	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
in	NULL
Neoplastic	NULL
Hematopathology	NULL
,	NULL
ed	NULL
.	NULL

Knowles	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
Williams	NULL
&	NULL
Wilkins	NULL
,	NULL
Baltimore	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

617-628	NULL
.	NULL

Schroeder	NULL
,	NULL
H.	NULL
W.	NULL
,	NULL
Jr.	NULL
,	NULL
&	NULL
Dighiero	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
288-294	NULL
.	NULL

Zheng	NULL
,	NULL
B.	NULL
,	NULL
Xue	NULL
,	NULL
W.	NULL
&	NULL
Kelsoe	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
372	NULL
,	NULL
556-559	NULL
.	NULL

Cheynier	NULL
,	NULL
R.	NULL
,	NULL
Henrichwark	NULL
,	NULL
S.	NULL
&	NULL
Wain-Hobson	NULL
,	NULL
S.	NULL
(	NULL
1998	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
1604-1610	NULL
.	NULL

Betz	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Rada	NULL
,	NULL
C.	NULL
,	NULL
Panell	NULL
,	NULL
R.	NULL
,	NULL
Milstein	NULL
,	NULL
C.	NULL
&	NULL
Neuberger	NULL
,	NULL
M.	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
2385-2388	NULL
.	NULL

Rogozin	NULL
,	NULL
I	NULL
.	NULL

B	NULL
.	NULL

&	NULL
Kolchanov	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1171	NULL
,	NULL
11-18	NULL
.	NULL

Neuberger	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Ebrenstein	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Klix	NULL
,	NULL
N.	NULL
,	NULL
Jolly	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Yelamos	NULL
,	NULL
J.	NULL
,	NULL
Rada	NULL
,	NULL
C.	NULL
&	NULL
Milstein	NULL
,	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

162	NULL
,	NULL
107-116	NULL
.	NULL

Golding	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
Gearhart	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

&	NULL
Glickman	NULL
,	NULL
B.	NULL
W.	NULL
(	NULL
1987	NULL
)	NULL
Genetics	NULL
115	NULL
,	NULL
169-176	NULL
.	NULL

Dorner	NULL
,	NULL
T.	NULL
,	NULL
Brezinschek	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Brezinschek	NULL
,	NULL
R.	NULL
I.	NULL
,	NULL
Foster	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Domiati-Saad	NULL
,	NULL
R.	NULL
&	NULL
Lipsky	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
2779-2789	NULL
.	NULL

Lebecque	NULL
,	NULL
S.	NULL
G.	NULL
&	NULL
Gearhart	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1717-1727	NULL
.	NULL

Shen	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Peters	NULL
,	NULL
A.	NULL
,	NULL
Baron	NULL
,	NULL
B.	NULL
,	NULL
Zhu	NULL
,	NULL
X	NULL
.	NULL

&	NULL
Storb	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Science	NULL
280	NULL
,	NULL
1750-1752	NULL
.	NULL

